

Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Coronary and Peripheral Vascular Angiography Main Results From the Randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT)

ACT Investigators*

Background—It remains uncertain whether acetylcysteine prevents contrast-induced acute kidney injury.

Methods and Results—We randomly assigned 2308 patients undergoing an intravascular angiographic procedure with at least 1 risk factor for contrast-induced acute kidney injury (age >70 years, renal failure, diabetes mellitus, heart failure, or hypotension) to acetylcysteine 1200 mg or placebo. The study drugs were administered orally twice daily for 2 doses before and 2 doses after the procedure. The allocation was concealed (central Web-based randomization). All analysis followed the intention-to-treat principle. The incidence of contrast-induced acute kidney injury (primary end point) was 12.7% in the acetylcysteine group and 12.7% in the control group (relative risk, 1.00; 95% confidence interval, 0.81 to 1.25; $P=0.97$). A combined end point of mortality or need for dialysis at 30 days was also similar in both groups (2.2% and 2.3%, respectively; hazard ratio, 0.97; 95% confidence interval, 0.56 to 1.69; $P=0.92$). Consistent effects were observed in all subgroups analyzed, including those with renal impairment.

Conclusions—In this large randomized trial, we found that acetylcysteine does not reduce the risk of contrast-induced acute kidney injury or other clinically relevant outcomes in at-risk patients undergoing coronary and peripheral vascular angiography.

Clinical Trial Registration—<http://www.clinicaltrials.gov>. Unique identifier: NCT00736866. (*Circulation*. 2011;124:1250-1259.)

Key Words: acute kidney injury ■ coronary angiogram ■ contrast media ■ angioplasty ■ acetylcysteine

Contrast-induced acute kidney injury represents a serious complication of procedures requiring administration of iodinated contrast media and is associated with the need for dialysis, prolonged hospitalization,^{1–3} increased costs, and mortality.^{4,5}

Editorial see p 1210 Clinical Perspective on p 1259

Acetylcysteine may prevent contrast-induced acute kidney injury by diminishing direct oxidative stress and by improving renal hemodynamics.^{6–8} It also represents a safe, inexpensive, and easily administered intervention. Since the first randomized trial testing acetylcysteine for the prevention of contrast-induced acute kidney injury was published,⁹ several trials were completed and reached inconsistent results.¹⁰ Such studies are limited by low statistical power (the median study size considering all previous trials was 80 patients), and most failed to meet quality standards such as allocation conceal-

ment, blinding, and intention-to-treat analysis.¹⁰ Systematic reviews have found high heterogeneity across studies, precluding definitive conclusions regarding the efficacy of acetylcysteine.^{10–16} Current guidelines disagree on whether acetylcysteine should be recommended for high-risk patients, although all recognize that more data are required.^{17–20}

The conflicting results of previous evidence have left clinicians uncertain about the effectiveness of acetylcysteine, and several specialists highlighted the need for a large-scale trial to inform clinical practice.^{13,21,22} To address this issue, we conducted the Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT), a multicenter randomized trial of acetylcysteine in patients at risk for contrast-induced acute kidney injury undergoing angiography.

Methods

Trial Design

ACT was an academic pragmatic randomized (concealed) controlled trial of acetylcysteine versus placebo in patients at risk for contrast-

Received April 19, 2011; accepted June 28, 2011.

*A complete list of the members of the ACT Investigators appears in the Acknowledgments at the end of the article.

From Research Institute, Hospital do Coração, São Paulo, Brazil. See Acknowledgments for a complete list of affiliations and locations.

The online-only Data Supplement is available with this article at <http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.111.038943/-DC1>.

Correspondence to Dr Otavio Berwanger, Research Institute, Hospital do Coração (HCor), Rua Abílio Soares 250, 12th Floor, CEP: 04005–000, São Paulo SP, Brazil. E-mail oberwanger@hcor.com.br

© 2011 American Heart Association, Inc.

Circulation is available at <http://circ.ahajournals.org>

DOI: 10.1161/CIRCULATIONAHA.111.038943

induced acute kidney injury undergoing an intravascular angiographic procedure conducted in 46 sites in Brazil. Participants, healthcare staff, data collectors, and outcome assessors were blinded to whether patients received acetylcysteine or placebo. All analyses followed the intention-to-treat principle. The trial was designed by the steering committee. A detailed description of the study design has been published previously,²³ and the trial was registered at <http://www.clinicaltrials.gov> (NCT00736866). The study was approved by the research ethics board of each participating institution.

Study Population

Patients undergoing coronary or peripheral arterial diagnostic intravascular angiography or percutaneous intervention were eligible for the trial if they had at least 1 risk factor for contrast-induced acute kidney injury: age >70 years, chronic renal failure (stable serum creatinine concentrations >132.6 $\mu\text{mol/L}$ [1.5 mg/dL]), diabetes mellitus, clinical evidence of congestive heart failure, left ventricular ejection fraction <0.45, or hypotension. We chose the inclusion criteria on the basis of independent risk factors validated by previous observational studies.^{24,25} We excluded patients on dialysis and those with ST-segment elevation myocardial infarction undergoing primary angioplasty (because they were unable to receive the study hydration protocol for at least 6 hours before the procedure). Women were excluded if they were pregnant, breastfeeding, or aged <45 years and did not use contraceptive methods.

Randomization

After providing written informed consent, patients were randomized in a 1:1 ratio to receive acetylcysteine or placebo. The allocation list was generated in random permuted blocks of variable size (4, 6, 8, or 10) and was stratified by site. To guarantee concealment of the allocation list, randomization was implemented through a 24-hour Web-based automated randomization system.

Study Interventions

The study drugs were packed in identical envelopes containing either 600 mg of oral powder acetylcysteine (Medley, Brazil) or placebo to be diluted in water. The powder and the solution were identical in appearance, taste, and smell. A dose of 1200 mg (2 envelopes) of acetylcysteine or placebo was administered orally every 12 hours, for 2 doses before and 2 doses after the procedure. All decisions about management of patients were at the discretion of the medical team, except that nontrial acetylcysteine was not allowed.

Hydration with 0.9% saline, 1 mL/kg per hour, from 6 to 12 hours before to 6 to 12 hours after angiography, was strongly recommended. However, changes in the total volume or speed of administration were permitted.

Study Procedures

Data were obtained at baseline, on the day of the angiography, and between 48 to 96 hours and at 30 days after angiography. Baseline data were collected immediately after randomization and before administration of hydration scheme and the study drugs. Data collected at baseline included demographic and clinical characteristics and the most recent serum creatinine level measured within the past 3 months under stable clinical conditions. On the day of the angiography, we collected data regarding the administration of the study drug, hydration scheme, and angiographic procedure. Between 48 to 96 hours after angiography, we assessed vital status, need for dialysis, need for another angiogram, and data regarding the administration of the study drugs and hydration and collected a blood sample for serum creatinine measurement. However, we strongly recommended to all investigators that the creatinine sample be collected within a 48- to 72-hour interval. Whenever >1 measurement was available during the period of 48 to 96 hours, the measure closer to 72 hours was used. We contacted the patients 30 days after the angiography to assess the need for dialysis and the vital status.

End Points

The primary end point was contrast-induced acute kidney injury, defined as a 25% elevation of serum creatinine above baseline between 48 and 96 hours after angiography. The secondary end points were as follows: a composite of death or need for dialysis in 48 to 96 hours and at 30 days; individual components of the composite outcome; elevation $\geq 44.2 \mu\text{mol/L}$ (0.5 mg/dL) in serum creatinine between 48 and 96 hours; cardiovascular deaths at 30 days; and other adverse events. Elevation $\geq 13.3 \mu\text{mol/L}$ (0.3 mg/dL) in serum creatinine, the Acute Kidney Injury Network criteria for acute kidney injury, was a post hoc defined end point.²⁶

Trial Management

The coordinating center resources included procedures manuals, slide sets, and a study Web site. Trained investigators and study coordinators at each site collected the data using a Web-based system. Data quality control was guaranteed by automated data entry checks, weekly contact with investigators, on-site monitoring, and central statistical monitoring.²⁷ General feedback was provided at investigators' meetings and in periodic newsletters.

Sample Size

On the basis of a recent meta-analysis, we anticipated an incidence of contrast-induced acute kidney injury at 48 to 96 hours of $\approx 15\%$.¹⁰ To detect a 30% relative risk reduction, with 90% statistical power and a 2-tailed α of 5%, we sought to include 2300 patients.

Statistical Analysis

All analyses were performed on an intention-to-treat basis, and no postrandomization exclusions were performed. Differences in discrete variables were evaluated by the χ^2 test. Continuous variables with skewed distributions were analyzed with the Wilcoxon rank sum test. The results of comparisons of proportions are presented as relative risks and their respective 95% confidence intervals (CIs). Secondary outcomes evaluated 30 days after randomization were analyzed with unadjusted Cox proportional hazards regression. The composite outcome death or need for dialysis was presented as Kaplan-Meier curves. Missing values were not imputed.

A subgroup effect was inferred when the χ^2 test for homogeneity of effects was statistically significant. The following prespecified subgroups were analyzed: age >70 or ≤ 70 years, gender, patients with or without previous renal failure (serum creatinine >132.6 $\mu\text{mol/L}$ [1.5 mg/dL]), presence of diabetes mellitus, and volume of contrast ≥ 140 mL. Subgroups were defined post hoc according to the following: time of measurement of creatinine after angiography, presence of acute coronary syndrome, type of contrast, and estimated glomerular filtration rate.

We conducted a prespecified random-effects meta-analysis to evaluate the results of the ACT in the context of previous randomized controlled trials of acetylcysteine versus placebo for preventing contrast-induced acute kidney injury (see additional methods in the online-only Data Supplement).²⁸ Because several systematic reviews addressing the same question were published to date, we screened references from previous reviews. This strategy was complemented by a comprehensive search on MEDLINE (2008 to present). The terms included in the electronic search were *contrast-induced nephropathy* combined with a sensitive strategy for the identification of randomized controlled trials.²⁹ We placed no language or publication status restrictions. We screened reference lists of all available primary studies and review articles to identify additional relevant citations. We found high heterogeneity between included trials. Thus, in an attempt to explain the high heterogeneity between trials, as a post hoc decision, we conducted stratified analyses according to prespecified methodological characteristics.

Statistical analyses were performed with the use of STATA/SE 10.0 (STATA Corp LP, College Station, TX) and SPSS release 16.0.2 (SPSS Inc, Chicago, IL).




Figure 1. Randomization, study drug adherence, and follow-up of the study patients.

Results

Study Participants

Between September 2008 and July 2010, a total of 2308 patients were enrolled in 46 sites in Brazil: 1172 patients were allocated to acetylcysteine and 1136 to placebo (Figure 1). A follow-up serum creatinine was not collected in 19 patients (1.6%) in the acetylcysteine group and in 17 patients (1.5%) in the placebo group. Information for outcomes at 30 days was available for all but 2 patients (99.9% with complete follow-up).

The baseline characteristics were well balanced between the groups (Table 1). The most common reasons for inclusion were diabetes mellitus, which was present in 1395 patients (60.4%), and age >70 years in 1202 patients (52.1%). Approximately half of the patients (1138) had an estimated creatinine clearance <60 mL/min (1 mL/s), and 35.4% of the sample was included during an acute coronary syndrome episode.

Compliance With Study Protocol and Characteristics of Angiography

From all of the included patients, 67.2% underwent diagnostic coronary angiographies, 28.8% were submitted to percutaneous coronary interventions, and 2.8% were submitted to peripheral vascular angiography (Table 2). Twenty-seven patients (1.2%) had their angiography cancelled after randomization but were kept in the analysis according to the intention-to-treat principle. Low-osmolarity contrast medium was the most common type of contrast used (74.7% of the cases). In approximately half of the included patients, the volume of contrast administered was >100 mL.

Compliance with all 4 study drug doses was >95%, and <1% of the patients did not receive the study drugs before angiography (Figure 1). Ninety-eight percent of the patients received intravenous hydration before and 98.0% after the procedure (Table 2). The median duration of hydration was 6 hours before and after angiography for both groups.

The mean times between angiography and follow-up serum creatinine sampling were 57.6 ± 16.9 and 58.2 ± 16.9 hours for

the acetylcysteine and placebo groups ($P=0.48$), respectively. For most patients (76.4%), serum creatinine was collected between 48 and 72 hours after angiography (Table 2).

End Points

The primary end point occurred in 147 of 1153 patients (12.7%) in the acetylcysteine group and in 142 of 1119 patients (12.7%) in the placebo group (relative risk, 1.00; 95% CI, 0.81 to 1.25; $P=0.97$) (Table 3). Results were similar when only patients ultimately submitted to angiography were considered: 144 of 1142 (12.6%) and 140 of 1111 (12.6%) patients in the acetylcysteine and placebo groups, respectively (relative risk, 1.00; 95% CI, 0.81 to 1.24; $P=0.99$). Elevation of $\geq 44.2 \mu\text{mol/L}$ (0.5 mg/dL) in creatinine after the procedure was similar between groups (relative risk, 1.04; 95% CI, 0.69 to 1.57; $P=0.85$). Doubling of creatinine was also similar in both groups (relative risk, 0.74; 95% CI, 0.36 to 1.52; $P=0.41$).

The incidence of the composite outcome death or need for dialysis at 30 days was 2.2% in the acetylcysteine group and 2.3% in the placebo group (hazard ratio, 0.97; 95% CI, 0.56 to 1.69; $P=0.92$) (Table 3 and Figure 2). The incidence of the composite outcome death, need for dialysis, or doubling in serum creatinine, as well as the incidence of the individual components of this composite outcome, was not statistically different between the acetylcysteine and placebo groups. Cardiovascular deaths at 30 days were similar between the experimental and control groups (hazard ratio, 0.99; 95% CI, 0.51 to 1.90; $P=0.97$). There was also no difference between groups for outcomes defined post hoc.

Subgroup Analysis

Effects on Patients With Impaired Renal Function

There was no effect of acetylcysteine in the 367 patients with baseline serum creatinine $>132.6 \mu\text{mol/L}$ (1.5 mg/dL) (acetylcysteine group: 12/188 and placebo group: 10/179; $P=0.75$ for homogeneity of effects) or in the 823 patients with estimated glomerular filtration rate between 30 and 60 mL/min per 1.73 m^2 (acetylcysteine group: 30/425 and

Table 1. Baseline Characteristics of Patients

Characteristic	Acetylcysteine (n=1172)	Placebo (n=1136)
Female sex, No. (%)	445 (38.0)	447 (39.3)
Age, mean±SD, y	68.0±10.4	68.1±10.4
Patients fulfilling inclusion criteria		
Serum creatinine >132.6 μmol/L (1.5 mg/dL), No. (%)	180 (15.4)	182 (16.0)
Diabetes mellitus, No. (%)	717 (61.2)	678 (59.7)
Known heart failure, No. (%)	116 (9.9)	104 (9.2)
Hypotension, No. (%)	3 (0.3)	2 (0.2)
Age >70 y, No. (%)	601 (51.3)	601 (52.9)
Acute coronary syndrome, No. (%)	419 (35.8)	397 (34.9)
History of hypertension, No. (%)	1,014 (86.5)	976 (85.9)
Previous medication		
Use of NSAIDs >7 d, No. (%)	63 (5.4)	59 (5.2)
Use of ACE inhibitor, No. (%)	698 (59.6)	661 (58.2)
Use of diuretics, No. (%)	442 (37.7)	401 (35.3)
Use of metformin, No. (%)	362 (30.9)	336 (29.6)
Serum creatinine, mg/dL	1.2±0.5	1.2±0.5
Estimated creatinine clearance, mL/min*		
Mean±SD	67.6±31.4	67.7±32.1
<30 mL/min, No. (%)	68 (5.8)	63 (5.5)
30 to 60 mL/min, No. (%)	515 (43.9)	492 (43.3)
>60 mL/min, No. (%)	589 (50.3)	581 (51.2)
Estimated glomerular filtration rate, mL/min per 1.73 m ² †		
Mean±SD	69.3±28.7	69.0±27.9
<30 mL/min, No. (%)	58 (4.9)	50 (4.4)
30 to 60 mL/min, No. (%)	428 (36.5)	404 (35.6)
>60 mL/min, No. (%)	686 (58.5)	682 (60.0)
Weight, mean±SD, kg	73.1±13.9	73.3±14.7

NSAID indicates nonsteroidal anti-inflammatory drug; ACE, angiotensin-converting enzyme. There was no statistically significant difference for baseline characteristics.

*Creatinine clearance estimated by the Cockcroft-Gault formula.

†Glomerular filtration rate estimated by the abbreviated Modification of Diet in Renal Disease study equation.

placebo group: 27/398) or <30 mL/min per 1.73 m² (acetylcysteine group: 6/56 and placebo group: 3/48; $P=0.73$ for homogeneity of effects), as shown in Figure 3.

Effects on Other Subgroups

The neutral effect of acetylcysteine on the risk of contrast-induced acute kidney injury was also consistent in those with or without diabetes mellitus ($P=0.42$) and across other subgroups such as patients aged >70 or ≤70 years ($P=0.52$), male or female patients ($P=0.55$), or exposure to high (≥140 mL) or low (<140 mL) volumes of contrast media ($P=0.79$), as shown in Figure 3. There was no effect of acetylcysteine in the subgroup of patients who had serum creatinine collected within 48 to 72 hours after angiography or in the subgroup in which serum creatinine was collected between 72 and 96 hours ($P=0.36$).

Table 2. Procedure Characteristics, Protocol Adequacy, and Hydration Scheme

Characteristic	Acetylcysteine (n=1172)	Placebo (n=1136)	<i>P</i>
Procedure, No. of patients/total No. (%)			0.79
Peripheral vascular angiography	32 (2.7)	32 (2.8)	
Coronary diagnostic angiography	778 (66.4)	774 (68.1)	
Percutaneous coronary intervention	347 (29.6)	318 (28.0)	
Not submitted to angiography	15 (1.3)	12 (1.1)	
Adherence to study drug, No. of patients/total No. (%)			
Dose 1	1160 (99.0)	1128 (99.3)	0.28
Dose 2	1136 (96.9)	1099 (96.7)	0.61
Dose 3	1129 (96.3)	1090 (95.9)	0.71
Dose 4	1120 (95.5)	1076 (94.7)	0.39
Hydration before procedure, No. of patients/total No. (%)			
NaCl or bicarbonate	1147 (97.9)	1119 (98.5)	0.25
NaCl 0.9%, 1 mL/kg per hour for 6 h	552 (47.1)	540 (47.5)	0.83
NaCl 0.9%, any scheme	1090 (93.0)	1071 (94.3)	0.21
NaCl 0.45%	3 (0.2)	0 (0.0)	0.25*
Bicarbonate 0.9%	60 (5.1)	52 (4.6)	0.55
Duration of hydration before procedure, h			
Median (interquartile range)	6 (4–6)	6 (4–6)	0.32
Hydration after procedure, No. of patients/total No. (%)			
NaCl or bicarbonate	1145 (97.7)	1115 (98.2)	0.53
NaCl 0.9%, 1 mL/kg per hour for 6 h	814 (69.4)	792 (69.7)	0.92
NaCl 0.9%, any scheme	1129 (96.3)	1100 (96.8)	0.58
NaCl 0.45%	1 (0.08)	0 (0)	1.00*
Bicarbonate 0.9%	66 (5.6)	62 (5.5)	0.85
Duration of hydration after procedure, h			
Median (interquartile range)	6 (6–6)	6 (6–6)	0.71
Contrast type, No. (%)†			
High osmolarity	253 (21.9)	256 (22.8)	
Low osmolarity	869 (75.1)	836 (74.4)	
Iso-osmolar	35 (3.0)	32 (2.8)	
Contrast volume, mL			
Median (interquartile range)	100 (70–130)	100 (70–130)	0.66
Additional angiography within 48–96 h after first procedure, No. (%)	38 (3.2)	47 (4.1)	0.25

(Continued)

Table 2. Continued

Characteristic	Acetylcysteine (n=1172)	Placebo (n=1136)	P
Timing of serum creatinine sampling after angiography, No. (%)‡			0.87
48 to ≤72 h	876 (76.3)	851 (76.6)	
72 to 96 h	272 (23.7)	260 (23.4)	

*Fisher exact test.

†In the acetylcysteine and placebo groups, 1157 and 1124 patients, respectively, were ultimately submitted to angiography. These are the denominators for type of contrast.

‡Serum creatinine after angiography was available for 1148 and 1111 patients in the acetylcysteine and placebo groups, respectively.

Adverse Events

The incidence of other serious adverse events was 1.3% in the acetylcysteine group and 2.2% in the placebo group ($P=0.09$) (Table I in the online-only Data Supplement). There was no difference between the study groups for any other adverse events, except that vomiting was less common in the acetylcysteine than in the placebo group (0.3% and 1.2%, respectively; $P=0.02$).

Updated Meta-Analysis

We identified 46 randomized controlled trials comparing acetylcysteine with placebo (or no acetylcysteine) in patients undergoing cardiac or peripheral angiography (Table II in the online-only Data Supplement). One study was excluded from our meta-analyses because no cases of contrast-induced acute kidney injury were observed in either the treatment or control group.³⁰ There was important heterogeneity between studies ($P<0.0001$; $I^2=59\%$). Therefore, we did not combine the results of all studies but instead attempted to identify the sources of heterogeneity by stratifying the analyses according to methodological characteristics of the trials.




Figure 2. Probability of death or need for dialysis from the day of randomization (day 0) to day 30 among patients in the acetylcysteine and placebo groups.

The pooled relative risk in studies with unclear or inadequate allocation concealment was 0.59 (95% CI, 0.43 to 0.82), with substantial heterogeneity across trials ($I^2=57\%$), whereas in studies with allocation concealment, the effect estimate (relative risk, 1.01; 95% CI, 0.75 to 1.37) was similar to that found in our study, with no remaining heterogeneity ($I^2=0\%$) (Figure 4). Meta-analyses stratified according to adequacy of all methodological characteristics (allocation concealment, double blinding, and intention-to-treat analysis) revealed a similar pattern. The pooled relative risk for low-quality studies was 0.63 (95% CI, 0.47 to 0.85; $I^2=56\%$) and for studies meeting all 3 methodological criteria was 1.05 (95% CI, 0.73 to 1.53; $I^2=0\%$).

Discussion

In this large randomized trial, acetylcysteine did not reduce the incidence of contrast-induced acute kidney injury. Acetylcysteine also did not show statistically sig-

Table 3. End Points

Outcomes	Acetylcysteine	Placebo	Relative Risk (95% CI)	P
Primary end point, No. of events/total No. (%)				
Contrast-induced acute kidney injury	147/1153 (12.7)	142/1119 (12.7)	1.00 (0.81–1.25)	0.97
Other end points, No. of events/total No. (%)				
End points in 48 to 96 h				
Doubling in serum creatinine	13/1153 (1.1)	17/1119 (1.5)	0.74 (0.36–1.52)	0.41
Elevation $\geq 44.2 \mu\text{mol/L}$ (0.5 mg/dL) in serum creatinine	45/1153 (3.9)	42/1119 (3.8)	1.04 (0.69–1.57)	0.85
Elevation $\geq 13.3 \mu\text{mol/L}$ (0.3 mg/dL) in serum creatinine	140/1153 (12.1)	123/1119 (11.0)	1.10 (0.88–1.39)	0.39
End points at 30 d				
Deaths or need for dialysis*	26/1171 (2.2)	26/1135 (2.3)	0.97 (0.56–1.69)	0.92
Death, need for dialysis, or doubling in serum creatinine	38/1171 (3.2)	41/1135 (3.6)	0.90 (0.58–1.39)	0.63
Deaths*	23/1171 (2.0)	24/1135 (2.1)	0.97 (0.54–1.73)	0.92
Need for dialysis*	3/1171 (0.3)	3/1135 (0.3)	0.87 (0.17–4.35)	0.86
Cardiovascular deaths*	18/1171 (1.5)	18/1135 (1.6)	0.99 (0.51–1.90)	0.97

CI indicates confidence interval.

*Results are hazard ratios with 95% CI and P values obtained by Cox regression.




Figure 3. Effect of acetylcysteine on contrast-induced acute kidney injury according to subgroup. CI indicates confidence interval; eGFR, estimated glomerular filtration rate.

nificant beneficial effects on other end points such as all-cause mortality and need for dialysis at 30 days. These results were consistent among all subgroups evaluated, including higher-risk patients such as those with renal failure, those with diabetes mellitus, and those who received the largest amounts of contrast.

Several strengths of the ACT reinforce our findings. It represents the largest trial testing the effects of acetylcysteine

for the prevention of contrast-induced acute kidney injury conducted to date. Although the incidence of contrast-induced acute kidney injury observed in the control group (12.7%) was somewhat lower than anticipated in our sample size calculation (15%), still the ACT would have adequate statistical power (84%) to detect a 30% decrease in the risk of contrast-induced acute kidney injury. We sought to ensure adequate methodological quality by using concealed random-




Figure 4. Meta-analyses of randomized controlled trials of acetylcysteine for preventing contrast-induced acute kidney injury stratified according to methodological criteria and the Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT) main result. I² represents the percentage of total variation across studies due to heterogeneity rather than chance. We considered all methodological criteria adequate when a trial had allocation concealment and was blinded and the analysis followed the intention-to-treat principle. CI indicates confidence interval; NA, not applicable.

ization; blinding patients, investigators, caregivers, and outcome assessors; analyzing data according to the intention-to-treat principle; and by having >98% of patients with complete follow-up data. We tested a high dose of acetylcysteine because previous evidence suggested that a dose of 1200 mg twice daily may be superior to a dose of 600 mg twice daily.^{16,31} Compliance to the study drugs was >95%, and cointerventions were well balanced between the groups. We used different methods to guarantee data quality including on-site monitoring, central statistical monitoring of the data, and data collection through a Web-based electronic data capture system.

More than 40 acetylcysteine trials have been completed in the past 10 years and have reached inconsistent results. One plausible explanation for the contradictory findings may be related to methodological quality.^{11,12,15} In this regard, our meta-analysis of smaller high-quality studies published before the ACT found neutral effects of acetylcysteine for the prevention of contrast-induced acute kidney injury with no heterogeneity between studies. On the other hand, the meta-analysis of trials with inadequate methodology suggested a beneficial effect of this intervention but with important between-trial heterogeneity. These results are in accordance with previous empirical evidence suggesting that trials with inadequate or unclear concealment of allocation or unclear description on blinding tend to overestimate the treatment effects.^{32,33} The ACT confirms the findings of smaller high-quality studies and, together with them, provides consistent evidence to support the lack of effect of acetylcysteine for the prevention of contrast-induced acute kidney injury.

Differences between the ACT and previous studies should be noted. Although some trials have enrolled only patients with renal failure, our trial sought to test the effects of acetylcysteine over a broader population at risk for contrast-induced acute kidney injury.^{17–19} In this regard, besides renal failure, our patients were selected on the basis of other well-established independent risk factors such as age >70 years, diabetes mellitus, and heart failure.^{2,3,24,25} The adoption of such broad inclusion criteria did not result in a low-risk population, as indicated by an overall incidence of contrast-induced acute kidney injury close to 13%, which was consistent among subgroups and similar to the incidence of previous trials, as shown in a previous systematic review.¹⁰ Moreover, patients with diabetes mellitus or with renal impairment represented >70% of our sample, and approximately half of our patients had a creatinine clearance <60 mL/min (1 mL/s). Thus, our higher-risk subgroups had a larger sample size representation than the previous studies. Finally, we did not find evidence of a subgroup effect in higher-risk patients. In particular, there was no effect of acetylcysteine in the subgroup of 367 patients with baseline serum creatinine >132.6 $\mu\text{mol/L}$ (1.5 mg/dL) or in the subgroups with estimated glomerular filtration rate <60 mL/min per 1.73 m² (total of 927 patients). Although the power to draw definitive conclusions for any of the subgroups is low, in all subgroups the results were very consistent. Therefore, it is unlikely that a beneficial effect exists for any subgroup. Although most of the previous studies tested oral acetylcysteine, as we did in the ACT, some employed

intravenous formulations.^{34–36} Even so, it is unlikely that the choice of intravenous instead of oral administration of acetylcysteine would influence our results. In this sense, the largest study using intravenous acetylcysteine also reached neutral results.³⁶

Our trial has limitations. First, we did not observe a large number of events that allowed us to assess the effects of acetylcysteine on end points such as mortality and need for dialysis. However, despite the wide CIs, the point estimates for these outcomes showed neutral effects of acetylcysteine. Second, we used creatinine as our marker of kidney injury, and some recent publications suggest that newer markers such as cystatin C are more reliable for detecting contrast-induced acute kidney injury.^{37,38} Nevertheless, results based on creatinine measures were consistent with those observed for other clinical end points. Additionally, a cystatin C ACT substudy involving >150 patients has now been completed, and the results should be available soon. Third, the median volume of contrast used was low (100 mL), and previous studies demonstrated an association between contrast volume and risk of contrast-induced acute kidney injury.^{2,24} However, we found no evidence of a subgroup effect in patients who received >140 mL of contrast. Fourth, cointerventions other than hydration were at the discretion of the attending physician. Nevertheless, they were well balanced between groups. Fifth, we used a definition for contrast-induced acute kidney injury (25% elevation of serum creatinine from baseline) that may have high sensitivity but lack specificity. However, this definition has been used by most trials in the field.¹³ Furthermore, previous studies demonstrated that even such minor increases predict a higher mortality and morbidity.^{2,5} In addition, we found no effect of acetylcysteine when considering other definitions of contrast-induced acute kidney injury, such as a 100% or a 44.2- $\mu\text{mol/L}$ (0.5-mg/dL) increase in serum creatinine, although the incidence of contrast-induced acute kidney injury and the study power are smaller with those definitions.

Studies have demonstrated persistence of contrast media up to 7 days after angiography in patients with contrast-induced acute kidney injury.^{39,40} In this study, patients received acetylcysteine every 12 hours, 2 doses before and 2 doses after angiography. Thus, it may be suggested this was not a long enough duration of therapy. Nonetheless, we believe that extending acetylcysteine therapy would not change the results of our trial because the peak of renal dysfunction occurs shortly after angiography (2 to 5 days), with fast normalization after it.^{41,42} Furthermore, previous trials that suggested acetylcysteine to be effective administered the drug for only up to 48 hours after angiography.^{9,34,43}

In conclusion, our trial showed that acetylcysteine did not result in a lower incidence of contrast-induced acute kidney injury or other renal outcomes. On the basis of our results, we do not recommend routine use of acetylcysteine for patients undergoing angiography. These findings have important implications for clinical practice and may prevent unnecessary procedure delays and health expenditures associated with the administration of acetylcysteine.

Acknowledgments

We are indebted to all of the study coordinators, investigators, and patients who participated in the ACT. Participants in the ACT are as follows: **Writing Committee:** From Research Institute, Hospital do Coração, São Paulo, Brazil: Otávio Berwanger, Alexandre B. Cavalcanti, Amanda G.M.R. Sousa, Anna M. Buehler, Alessandra A. Kodama, Mariana T. Carballo, Vitor O. Carvalho, Celso Amodeo, Leda D. Lotaif, José Eduardo Sousa. From Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil: Amanda G.M.R. Sousa. **Statistical Analyses:** Mariana T. Carballo, Elivane S. Victor. **Trial Steering Committee:** Otávio Berwanger (chair), Alexandre B. Cavalcanti, Amanda G.M.R. Sousa, José Eduardo Sousa, Celso Amodeo, Leda D. Lotaif. **Trial Management Team:** Otávio Berwanger (chief investigator), Alexandre B. Cavalcanti (project manager), Anna M. Buehler (project manager), Mariana T. Carballo (statistician), Alessandra A. Kodama (data management), Eliana Santucci (research coordinator), Carlos E. S. Cardoso (data management), Dalmo da Silva (data management), Adailton L. Mendes (senior computer programmer), José Lobato (chief computer programmer). **Investigator Sites:** *Associação Hospital de Bauru*, Bauru, São Paulo: G. Prates, H. Yokoyama, P. Almeida, C. Pessoa; *Cardiocenter Hospital Santa Paula*, João Pessoa, Paraíba: H. Martins, M. Lopes, M. Barros; *Fundação Pública Estadual Hospital Gaspar Vianna*, Belém, Pará: H. Reis, C. Cordeiro; *Hospital Bandeirantes*, São Paulo: H. Castello, M. Cantarelli, S. Ferreira; *Hospital Barra Dor*, Rio de Janeiro: C. Mattos, M. Rati, C. Medeiros; *Hospital Beneficência Portuguesa*, São Paulo: J.A. Mangione, M.F. Mauro, S.A. Cristóvão, N.M. Carnieto, L.C. Rocha, D.F. Maksud, C. Barbosa; *Hospital Cardiologico Constantini*, Curitiba, Paraná: C. Costantini, S. Tarbine, M. Santos, C. Ortiz, A. Souza; *Hospital Copa Dor*, Rio de Janeiro: C. Mattos, L. Duarte; *Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo*, Ribeirão Preto, São Paulo: J. Marin Neto, G. Figueiredo, D. Lemos, F. Braga, G. Novaes, F. Oliveira, M. Tonani; *Hospital das Clínicas da Faculdade Federal de Pernambuco*, Recife, Pernambuco: E. Victor Filho, E. Rocha; *Hospital de Terapia Intensiva HTI*, Teresina, Piauí: P. Nunes, A. Sá Filho, I. Lima; *Hospital do Coração de Juiz de Fora*, Juiz de Fora, Minas Gerais: A. Muniz, J. Loures, A. Abraão; *Hospital do Coração de São Paulo*, São Paulo: J. Sousa, A. Moreira; *Hospital do Coração do Brasil*, Brasília, Distrito Federal: E. Araújo, L. Sousa, A. Fonseca; *Hospital Escola Álvaro Alvim*, Campos, Rio de Janeiro: J. Soares, C. Cunha; *Hospital Felício Rocho*, Belo Horizonte, Minas Gerais: J. Saad, F. Câmara, E. Falcheto; *Hospital Maternidade e Pronto Socorro Santa Lúcia*, Poços de Caldas, Minas Gerais: R. Bergo, F.T.C. Dall'Orto, R. Almeida, R. Mendes; *Hospital Moinhos de Vento*, Porto Alegre, Rio Grande do Sul: M. Wainstein, J. Ribeiro, C. Teixeira; *Hospital Quinta Dor*, Rio de Janeiro: C. Mattos; *Hospital Regional do Sul de Minas*, Varginha, Minas Gerais: F. Cunha, F.T.C. Dall'Orto, J. Lisboa, D. Osugui; *Hospital Samaritano*, São Paulo: F. Stella, J. Almeida, A. Stella, F. Assunção, S. Souza, J. Malachia, P. Buononato; *Hospital Santa Catarina*, Blumenau, Santa Catarina: D. Zappi, M. Linhares, M. Junckes; *Hospital Santa Helena São Francisco Cardio Vida*, Aparecida de Goiânia, Goiás: J. Guimarães, D. Araújo Filho; *Hospital Santa Lucinda*, Sorocaba, São Paulo: J. Maiello, E. Seixas; *Hospital Santa Marcelina*, São Paulo: B. Almeida, B. Janella, M. Almeida; *Hospital São José do Avaí*, Itaperuna, Rio de Janeiro: A. Silva, A. Marco, A. Teixeira, J. Pinto; *Hospital SOS Cardio*, Florianópolis, Santa Catarina: L. São Thiago, L. Giuliano, F. Aranha, D. Arante; *Hospital UDI*, São Luís, Maranhão: M. Barbosa, F. Aguiar Filho, C. Gama; *Hospital Universitário São José*, Belo Horizonte, Minas Gerais: C. Arêas, M. Lacerda, I. Freitas, F.T.C. Dall'Orto; *INCOR Hemocardio*, Natal, Rio Grande do Norte: L.A. Oliveira, I.R. Oliveira, F. Pinheiro, C. Amaral; *INCORPI Hospital Forneceadores de Cana*, Piracicaba, São Paulo: L. Gubolino, P. Teixeira, J.F. Toledo; *Instituto Dante Pazzanese de Cardiologia*, São Paulo: A. Sousa, F. Feres, M. Centemero, J.R. Costa, V. Esteves, J. Polacini, R. Viana; *Instituto de Cardiologia*, São José, Santa Catarina: L. São Thiago, L. Giuliano, M. Antunes, R. Conceição; *Instituto de Cardiologia RGS Fundação Universitária de Cardiologia*, Porto Alegre, Rio Grande do Sul: A. Azmus, A. Quadros; *Instituto de Clínicas e Cirurgia de Juiz de Fora Hospital*

Monte Sinai, Juiz de Fora, Minas Gerais: G. Ramalho, R. Santos; *Instituto de Moléstias Cardiovasculares*, São José do Rio Preto, São Paulo: P. Garzon, D. Faria, C. Queirantes, P. Galeazzi, V. Cavallini, R. Carvalho; *Instituto do Coração do Triângulo Mineiro*, Uberlândia, Minas Gerais: R. Botelho, C. Rosa, M. Seabra, A. Pereira, S. Reis, V. Pereira, S. Cunha, P. Vitor; *Instituto do Coração de Taguatinga Hospital Anchieta*, Taguatinga, Distrito Federal: P. Motta, E. Osterne, F. X. Souza, V. Motta, M.S. Heleno, K.M. Ramalho; *Instituto Nacional de Cardiologia Laranjeiras*, Rio de Janeiro: H. Cramer, B. Santos Júnior, B. Tura, D. Cook, D. Justen; *Natal Hospital Center*, Natal, Rio Grande do Norte: M. Paiva, E. Czochra, K.C. Potengi, F. Pinheiro; *Santa Casa de Limeira*, Limeira, São Paulo: P. Teixeirense, J.F. Toledo, L. Gubolino; *Santa Casa de Marília*, Marília, São Paulo: A. Labrunie, P. Andrade, M. Tebet; *Santa Casa de Misericórdia de Juiz de Fora*, Juiz de Fora, Minas Gerais: A. Muniz, J. Loures, A. Abraão, M.S. Vankeulen, N.J. Pedroso, *Santa Casa de Porto Alegre*, Porto Alegre, Rio Grande do Sul: G. Nunes, A. Oliveira, C. Roehrig, I. Colnaghi; *Santa Casa de São Paulo*, São Paulo: F. Stella, M. Candeias, L. Scatamburlo, V. Kloth; *UNISUL Hospital Socimed*, Tubarão, Santa Catarina: S. Abreu, J. Lima.

Sources of Funding

The ACT is funded by the Brazilian Ministry of Health (Programa Hospitais de Excelência a Serviço do SUS). The sponsor had no role in analysis, study design, or decision to publish these results.

Disclosures

None.

References

1. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, Farid N, McManamon PJ. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. *N Engl J Med*. 1989;320:143-149.
2. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. *Am J Med*. 1997;103:368-375.
3. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, Lansky AJ, Moussa I, Stone GW, Moses JW, Leon MB, Mehran R. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. *Am J Cardiol*. 2005;95:13-19.
4. McCullough PA, Stacul F, Becker CR, Adam A, Lameire N, Tumlin JA, Davidson CJ. Contrast-Induced Nephropathy (CIN) Consensus Working Panel: executive summary. *Rev Cardiovasc Med*. 2006;7:177-197.
5. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. *Circulation*. 2002;105:2259-2264.
6. Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Machado Cesar LA, Seguro AC. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. *Nephrol Dial Transplant*. 2004;19:1803-1807.
7. Lopez BL, Snyder JW, Birenbaum DS, Ma XI. N-Acetylcysteine enhances endothelium-dependent vasorelaxation in the isolated rat mesenteric artery. *Ann Emerg Med*. 1998;32:405-410.
8. Heyman SN, Rosen S, Khamaisi M, Idee JM, Rosenberger C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. *Invest Radiol*. 2010;45:188-195.
9. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. *N Engl J Med*. 2000;343:180-184.
10. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. *Ann Intern Med*. 2008;148:284-294.
11. Nallamothu BK, Shojania KG, Saint S, Hofer TP, Humes HD, Moscucci M, Bates ER. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. *Am J Med*. 2004;117:938-947.

12. Bagshaw SM, McAlister FA, Manns BJ, Ghali WA. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. *Arch Intern Med*. 2006;166:161–166.
13. Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. *JAMA*. 2006;295:2765–2779.
14. Zagler A, Azadpour M, Mercado C, Hennekens CH. N-Acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. *Am Heart J*. 2006;151:140–145.
15. Gonzales DA, Norsworthy KJ, Kern SJ, Banks S, Sieving PC, Star RA, Natanson C, Danner RL. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. *BMC Med*. 2007;5:32.
16. Trivedi H, Daram S, Szabo A, Bartorelli AL, Marenzi G. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. *Am J Med*. 2009;122:874–815.
17. Benko A, Fraser-Hill M, Mager P, Capusten B, Barrett B, Myers A, Owen RJ. Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy. *Can Assoc Radiol J*. 2007;58:79–87.
18. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB III, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). *J Am Coll Cardiol*. 2006;47:1–121.
19. Wijns W, Kolh P, Danchin N, Di MC, Falk V, Folliquet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirllet C, Pomar JL, Reifart N, Ribichini FL, Schali MJ, Sergeant P, Serruys PW, Silber S, Sousa UM, Taggart D, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE, Widimsky P, Kolh P, Alfieri O, Dunning J, Elia S, Kappetein P, Lockowandt U, Sarris G, Vouhe P, Kearney P, von Segesser L, Agewall S, Aladashvili A, Alexopoulos D, Antunes MJ, Atalar E, Brutel dR, Doganov A, Eha J, Fajadet J, Ferreira R, Garot J, Halcox J, Hasin Y, Janssens S, Kervinen K, Laufer G, Legrand V, Nashef SA, Neumann FJ, Niemela K, Nihoyannopoulos P, Noc M, Piek JJ, Pirk J, Rozenman Y, Sabate M, Starc R, Thielmann M, Wheatley DJ, Windecker S, Zembala M. Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2010;31:2501–2555.
20. Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA, Tumlin J. Strategies to reduce the risk of contrast-induced nephropathy. *Am J Cardiol*. 2006;98:59–77.
21. Caixeta A, Mehran R. Evidence-based management of patients undergoing PCI: contrast-induced acute kidney injury. *Catheter Cardiovasc Interv*. 2010;75:15–20.
22. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. *Circulation*. 2006;113:1799–1806.
23. Costa E, Reis H, de Assis GM, Cardoso GL, Barbosa MM, de Aguiar Filho FA, Gama CA, Silva MG, Aguiar BM, Ferreira MG, Feitosa GS, Victor Filho E, Rocha EB, Paiva MS, Czochra ER, Oliveira LA, de Oliveira IR, Pinheiro F, Dourado GO, Luna Filho AL, Pacheco A, Nunes PM, de Sá Filho AP, Martins HC, Lopes MA, Barros MA, Mattos C, Neves MA, Medeiros CR, Mattos C, Duarte L, Mattos C, Cramer H, Santos B Jr, Tura BR, Rodrigues CV, Teixeira LA, Alves MA, Soares JS, da Cunha CC, da Silva AC, Barcelos AM, Teixeira MA, Pinto JS, Saad JA, Mandil A, Falcheto E, Arêas CA, Dall'Orto FT, Freitas IF, Botelho RV, Seabra MD, Rosa CA, Pereira AD, Reis SS, Pereira VJ, Cunha SM, Ramalho GM, dos Santos RR, Muniz AJ, Loures JB, Amorim T, Muniz AJ, Loures JB, Abraão AC, Padilha RM, Sousa JE, Sousa AG, Moreira AC, Sousa AG, Feres F, Centemero M, Costa R, Esteves V, Almeida BO, Janella BL, Almeida MC, Stella FP, Almeida JD, Kloth VR, Mangione JA, Mauro MF, Tallo F, Santos DJ, Castello H, Cantarelli MJ, Baradel PB, Stella FP, das Candeias MO, Kloth VR, Maiello JR, Seixas EA, Teixeira PT, de Toledo JF, Gubolino LA, Prates GJ, Yokoyama H, de Almeida P, Pessoa CM, Machado NC, Garzon PG, Antonângelo AF, Galeazzi PB, Queirantes CS, Cavalini VH, Labrunie A, de Andrade PB, Tebet MA, Devito FS, Farias CE, Nicolela EL Jr, Passos HM, Rubio P, Gubolino LA, Teixeira PT, de Toledo JF, Nunes GL, Roehrig C, de Oliveira AT, Wainstein MV, Ribeiro JP, Teixeira C, Atallah TN, Gomes C, Morelli H, Costantini CR, Tarbine SG, Santos MF, Ortiz CC, de Souza AB, Pecoits-Filho R, Koppe G, Hoffman PD, Faria Neto JR, Wang R, Cury C, Stadler N, Nercolini DC, Zanuzzi C, Bueno RR, Guerios EE, Tarastchuk JC, Peixoto ML, Labrunie A, de Andrade PB, Tebet MA, Thiago LE, Giuliano LC, Aranha FG, Misiak M, Thiago LE, Giuliano LC, Antunes MH, da Conceição RS, Abreu SM, Preve JC, Guimarães JS, de Araújo Filho D, Araújo EC, de Sousa LN, Fonseca AG, da Motta PA, Osterne EC, da Motta VP, Zimmermann AC. Rationale, design, and baseline characteristics of the Acetylcysteine for Contrast-Induced nephropathy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy. *Trials*. 2009;10:38.
24. Bartholomew BA, Harjai KJ, Dukkkipati S, Boura JA, Yerkey MW, Glazier S, Grines CL, O'Neill WW. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. *Am J Cardiol*. 2004;93:1515–1519.
25. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol*. 2004;44:1393–1399.
26. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care*. 2007;11:31.
27. Buyse M, George SL, Evans S, Geller NL, Ranstam J, Scherrer B, Lesaffre E, Murray G, Edler L, Hutton J, Colton T, Lachenbruch P, Verma BL. The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. *Stat Med*. 1999;18:3435–3451.
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7:177–188.
29. Lefebvre C, Manheimer E, Glanville J; on behalf of Cochrane Information Retrieval Methods Group. Chapter 6: Searching for studies. In: Higgins JP, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions*. Chichester, UK: John Wiley & Sons Ltd.; 2008.
30. Kotlyar E, Keogh AM, Thavapalachandran S, Allada CS, Sharp J, Dias L, Muller D. Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures: a randomised controlled trial. *Heart Lung Circ*. 2005;14:245–251.
31. Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, Paolo EP, Golia B, Lepore S, Riviezzo G, Scarpato P, Focaccio A, Libreria M, Bonizzoni E, Ricciardelli B. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. *Eur Heart J*. 2004;25:206–211.
32. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. *BMJ*. 2001;323:42–46.
33. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA*. 1995;273:408–412.
34. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De MM, Galli S, Fabbicocchi F, Montorsi P, Veglia F, Bartorelli AL. N-Acetylcysteine and contrast-induced nephropathy in primary angioplasty. *N Engl J Med*. 2006;354:2773–2782.
35. Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, Fuernau G, Erbs S, Linke A, Diederich KW, Nowak M, Desch S, Gutberlet M, Schuler G. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate Percutaneous Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. *J Am Coll Cardiol*. 2010;55:2201–2209.
36. Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al SA, Sutander A, Williams T, Fox RS, Levin A. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. *Am Heart J*. 2004;148:422–429.
37. Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Pietruck F, Janssen O, Philipp T, Kribben A. Early detection of acute renal failure by serum cystatin C. *Kidney Int*. 2004;66:1115–1122.
38. Hoffmann U, Fischereder M, Kruger B, Drobni W, Kramer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-

- induced nephropathy seems questionable. *J Am Soc Nephrol.* 2004;15:407–410.
39. D'Elia JA, Gleason RE, Alday M, Malarick C, Godley K, Warram J, Kaldany A, Weinrauch LA. Nephrotoxicity from angiographic contrast material: a prospective study. *Am J Med.* 1982;72:719–725.
40. Jakobsen JA, Berg KJ, Kjaersgaard P, Kolmannskog F, Nordal KP, Nossen JO, Rootwelt K. Angiography with nonionic x-ray contrast media in severe chronic renal failure: renal function and contrast retention. *Nephron.* 1996;73:549–556.
41. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. *AJR Am J Roentgenol.* 2004;183:1673–1689.
42. Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and athero-embolism: a critical review. *Am J Kidney Dis.* 1994;24:713–727.
43. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, Fan K, Lee CH, Lam WF. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. *JAMA.* 2003;289:553–558.

CLINICAL PERSPECTIVE

Contrast-induced acute kidney injury is associated with the need for dialysis, prolonged hospitalization, and mortality. Its incidence in patients with risk factors (kidney failure, diabetes mellitus, or advanced age) varies between 9% and 38%. Previous acetylcysteine trials had substantial risk of bias and were underpowered. We conducted a randomized trial of acetylcysteine versus placebo in 2308 patients at risk for contrast-induced acute kidney injury (age >70 years, renal failure, diabetes mellitus, heart failure, or hypotension) undergoing an intravascular angiographic procedure. Allocation was concealed; patients, health staff, and outcome assessors were blinded, and analysis followed the intention-to-treat principle. We administered 1200 mg of acetylcysteine or placebo every 12 hours, twice before and twice after the angiography. We found no effect of acetylcysteine on contrast-induced acute kidney injury, the primary end point (12.7% vs 12.7% in the acetylcysteine and placebo groups, respectively; relative risk, 1.00; 95% confidence interval, 0.81 to 1.25; $P=0.97$). There was also no effect on any of the secondary outcomes or for any subgroup. We conducted a meta-analysis to assess the results of the Acetylcysteine for Contrast-Induced Nephropathy Trial in the context of 45 trials on the same subject and found a huge variation in the effect on contrast-induced acute kidney injury, although those with adequate methodological criteria did not show any clinical benefit of acetylcysteine. In conclusion, our trial, the largest conducted to date, showed that acetylcysteine is ineffective to prevent contrast-induced acute kidney injury. Therefore, we do not recommend routine use of acetylcysteine for patients undergoing angiography.

Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Coronary and Peripheral Vascular Angiography: Main Results From the Randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT)
ACT Investigators

Circulation. 2011;124:1250-1259; originally published online August 22, 2011;
doi: 10.1161/CIRCULATIONAHA.111.038943

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the
World Wide Web at:

<http://circ.ahajournals.org/content/124/11/1250>

Data Supplement (unedited) at:

<http://circ.ahajournals.org/content/suppl/2011/08/18/CIRCULATIONAHA.111.038943.DC1>
<http://circ.ahajournals.org/content/suppl/2013/10/14/CIRCULATIONAHA.111.038943.DC2>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Circulation* is online at:
<http://circ.ahajournals.org/subscriptions/>

Supplemental Material

Methods for the Updated Meta-Analysis

Eligibility Criteria

We included randomized placebo-controlled trials that evaluated pharmacological interventions N-Acetylcysteine to prevent contrast-induced acute kidney injury (CI-AKI) in patients undergoing diagnostic and therapeutic coronary or peripheral angiography. Trials were eligible regardless of their publication status, language or primary objectives. We excluded: trials that did not evaluate the number of patients with CI-AKI, duplicate publications or sub studies of included trials.

Search Strategy

Since many systematic reviews on CI-AKI prevention methods were published to date, as a starting point, we decided to screen references from previous reviews. This strategy was complemented by a comprehensive search on MEDLINE/PubMed version (2008 to the present). We placed no language or publication status restrictions. We screened reference lists of all available primary studies and review articles to identify additional relevant citations. The search results were uploaded into a reference management program (Reference Manager 12.0).

The terms included in the electronic search were “Contrast-induced nephropathy” combined with a sensitive strategy for the identification of randomized controlled trials.¹

Assessment of Study Eligibility

We screened all citations (i.e., titles and abstracts) identified in our search. Screeners (A.B.C. and O.B.) only excluded citations if it was clear that the article was not a report of a randomized controlled trial or the trial did not include a pharmacological intervention to prevent CIN as an experimental intervention. We obtained the full text article of all citations selected to undergo full review in the screening process. Individuals then determined eligibility of these full text articles. All

screening and eligibility decisions were conducted by two independent reviewers, and disagreements were resolved by third party adjudication.

Data collection

Two reviewers (A.B.C. and O.B.) independently extracted data from all trials that fulfilled our eligibility criteria. Disagreements were settled by a third reviewer.

We extracted the following descriptive data from all eligible trials: first author or study name, year of publication, patient population, treatment and control interventions, definition of CI-AKI and the number of patients randomized to the treatment and control groups, as well as the number of patients who had CI-AKI in each group.

Quality Assessment

We assessed the methodological quality of the trials by evaluating the original reports, the trial protocols (when published) and through attempted contact of the authors. We assessed the following risk of bias domains:

Allocation concealment

- Adequate (A): Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study.
- Unclear (B): Randomisation stated but no information on method used is available.
- Inadequate (C): Method of randomisation used such as alternate medical record numbers or unsealed envelopes; any information in the study that indicated that investigators or participants could influence intervention group.

Blinding

- Blinding of investigators: Yes/no/not stated/ Unclear or inadequate (if the study was described as double blind, but the method of blinding was not described or is not compatible with blinding).
- Blinding of participants: Yes/no/not stated/ Unclear or inadequate (if the study was described as double blind, but the method of blinding was not described or is not compatible with blinding).
- Blinding of outcome assessors: Yes/no/not stated/ Unclear or inadequate (if the study was described as double blind, but the method of blinding was not described or is not compatible with blinding).

Intention-to-treat

- Yes: Specifically reported by authors that intention-to-treat analysis was undertaken and this was confirmed on study assessment.
- Yes: Not stated but confirmed on study assessment.

- No: Not reported and lack of intention-to-treat analysis confirmed on study assessment.(Patients who were randomised were not included in the analysis because they did not receive the study intervention, they withdrew from the study or were not included because of protocol violation).
- No: Stated but not confirmed upon study assessment.
- Not stated.

* Obs.: Our evaluation will be independent of authors' claim of ITT analysis, i.e., a study might be considered by us as analyzed according to ITT principle even if there is no such statement as long as we confirm that on study assessment. The opposite is also true, if a study is reported as being ITT but we might consider it not to be ITT depending on our evaluation.

Statistical Analysis

CI-AKI from all included RCTs was combined to estimate the pooled risk ratio (RR) with 95% confidence interval (CI) using a random-effects model.² The presence of heterogeneity across studies was evaluated using I^2 statistics and standard χ^2 tests for homogeneity for each outcome analysis.³ An I^2 value represents the percentage of total variation across studies due to heterogeneity rather than chance. We conducted the analyses using Stata 11.0 (College Station, Texas, USA) and RevMan 5.1 (Cochrane Collaboration, Oxford, UK).

Supplemental Table 1. **Adverse Events.** *

	Acetylcysteine	Placebo	Relative risk	p
	No. of events / total no. (%)		(CI 95%)	
Any Serious adverse events†	15/1172 (1.3)	25/1136 (2.2)	0.58 (0.31; 1.10)	0.09
Any Adverse Events	89/1172 (7.6)	80/1136 (7.0)	1.08 (0.81; 1.44)	0.61
Chest pain	25/1172 (2.1)	14/1122 (1.2)	1.73 (0.90; 3.31)	0.09
Dyspnea	19/1172 (1.6)	13/1123 (1.1)	1.42 (0.70; 2.85)	0.33
Nausea	8/1172 (0.7)	15/1136 (1.2)	0.52 (0.22; 1.21)	0.12
Vomit	4/1172 (0.3)	14/1136 (1.2)	0.28 (0.09; 0.84)	0.02
Diarrhea	7/1172 (0.6)	6/1136 (0.5)	1.13 (0.38; 3.35)	0.82

* CI denotes Confidence Interval.

† Includes stroke, myocardial infarction, pneumonia, sepsis and acute pulmonary edema.

Supplemental Table 2. **Summary of results and study quality characteristics of randomized controlled trials evaluating acetylcysteine for preventing contrast-induced nephropathy in patients undergoing invasive angiography.**

Study	Year	Acetylcysteine		Control		Allocation concealment	Double-blind	Intention-to-treat analysis
		no. of events	total no.	no. of events	total no.			
Allaqaband ⁵	2002	8	45	6	40	Not reported	No	No
Amini ⁶	2009	5	45	6	42	Yes	Yes	Yes
Azmus ⁷	2005	14	196	17	201	Not reported	Yes	No
Baker ⁸	2003	2	41	8	39	Not reported	No	Yes
Baskurt ⁹	2009	7	73	5	72	Not reported	No	Yes
Briguori ¹⁰	2002	6	92	10	91	Not reported	No	No
Carbonell ¹¹	2007	11	107	11	109	Yes	Yes	Yes
Carbonell ¹²	2010	2	39	10	42	Not reported	Yes	No
Castini ¹³	2010	9	53	7	51	Not reported	No	Yes
Coyle ¹⁴	2006	6	68	1	69	No	No	No
Diaz-Sandoval ¹⁵	2002	2	25	13	29	Yes	Yes	No
Drager ¹⁶	2004	1	13	2	11	Not reported	Yes	No
Durham ¹⁷	2002	10	38	9	41	Not reported	No	No
Efrati ¹⁸	2003	0	24	2	25	Not reported	Yes	No
El Mahmoud ¹⁹	2003	3	60	2	60	Not reported	No	No
Ferrario ²⁰	2009	8	99	6	101	Yes	Yes	Yes
Fung ²¹	2004	8	46	6	45	Yes	No	Yes
Goldenberg ²²	2004	4	41	3	39	Yes	Yes	No
Gomes ²³	2005	8	77	8	79	Yes	Yes	No
Gulel ²⁴	2005	3	25	2	25	Not reported	No	No
Heng ²⁵	2008	2	28	3	32	Not reported	Yes	No
Kay ²⁶	2003	4	102	12	98	Not reported	Yes	No
Kefer ²⁷	2003	2	53	3	51	No	No	No
Kim ²⁸	2010	3	80	7	86	Not reported	No	Yes
Kimmel ²⁹	2008	1	19	2	17	Not reported	Yes	Yes
Kinbara ³⁰	2009	0	15	4	15	Not reported	No	Yes

Kotlyar ³¹	2005	0	41	0	19	Yes	No	No
Lawlor ³²	2007	2	25	2	25	Yes	Yes	Yes
Loutrianakis ³³	2003	6	24	3	23	Not reported	Not reported	Not reported
MacNeill ³⁴	2003	1	21	7	22	Not reported	Yes	No
Marenzi ³⁵	2006	17	235	39	119	Not reported	No	No
Miner ³⁶	2004	9	89	18	22	Not reported	Yes	Yes
Moore ³⁷	2006	3	11	0	9	Not reported	No	Yes
Namgung ³⁸	2005	4	25	10	23	No	No	No
Ochoa ³⁹	2004	3	36	11	44	Not reported	Yes	Yes
Oldemeyer ⁴⁰	2003	4	49	3	47	Not reported	Yes	No
Rashid ⁴¹	2004	3	46	3	48	Yes	Yes	No
Reinecke ⁴²	2007	6	114	7	115	Not reported	Not reported	Yes
Sadat ⁴³	2010	1	21	3	19	Not reported	No	Yes
Sandhu ⁴⁴	2006	3	53	0	53	Yes	No	No
Seyon ⁴⁵	2007	1	20	2	20	No	Yes	Yes
Shyu ⁴⁶	2002	2	60	15	61	Not reported	No	No
Sinha ⁴⁷	2004	5	35	6	35	No	No	No
Thiele ⁴⁸	2010	18	123	25	126	Not reported	No	Yes
Vallero ⁴⁹	2002	4	47	4	53	Not reported	No	Not reported
Webb ⁵⁰	2004	25	220	24	227	Yes	Yes	Yes

References

- (1) Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: The Cochrane Collaboration, editor. *Cochrane Handbook for Systematic Reviews of Interventions*. Version 5.0.0 (Updated February 2008) ed. 2008.
- (2) DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7:177-188.
- (3) Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-60.
- (4) DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7:177-188.
- (5) Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, Bajwa TK. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. *Catheter Cardiovasc Interv*. 2002;57:279-283.
- (6) Amini M, Salarifar M, Amirbaigloo A, Masoudkabar F, Esfahani F. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial. *Trials*. 2009;10:45.
- (7) Azmus AD, Gottschall C, Manica A, Manica J, Duro K, Frey M, Bulcão L, Lima C. Effectiveness of acetylcysteine in prevention of contrast nephropathy. *J Invasive Cardiol*. 2005;17:80-84.
- (8) Baker CS, Wragg A, Kumar S, De PR, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. *J Am Coll Cardiol*. 2003;41:2114-2118.
- (9) Baskurt M, Okcun B, Abaci O, Dogan GM, Kilickesmez K, Ozkan AA, Ersanli M, Gurmen T. N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy. *Eur J Clin Invest*. 2009;39:793-799.
- (10) Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, Lepore S, Librera M, Villari B, Colombo A, Ricciardelli B. Acetylcysteine and contrast agent-associated nephrotoxicity. *J Am Coll Cardiol*. 2002;40:298-303.
- (11) Carbonell N, Blasco M, Sanjuán R, Pérez-Sancho E, Sanchis J, Insa L, Bodí V, Núñez J, García-Ramón R, Miguel A. Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial. *Int J Cardiol*. 2007;115:57-62.
- (12) Carbonell N, Sanjuan R, Blasco M, Jorda A, Miguel A. N-acetylcysteine: short-term clinical benefits after coronary angiography in high-risk renal patients. *Rev Esp Cardiol*. 2010;63:12-19.
- (13) Castini D, Lucreziotti S, Bosotti L, Salerno Uriarte D, Sponzilli C, Verzoni A, Lombardi F. Prevention of contrast-induced nephropathy: a single center randomized study. *Clin Cardiol*. 2010;33:E63-E68.
- (14) Coyle LC, Rodriguez A, Jeschke RE, Simon-Lee A, Abbott KC, Taylor AJ. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. *Am Heart J*. 2006;151:1032-1012.
- (15) Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). *Am J Cardiol*. 2002;89:356-358.

- (16) Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Machado Cesar LA, Seguro AC. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. *Nephrol Dial Transplant*. 2004;19:1803-1807.
- (17) Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M, Keltz J, Dutka P, Marzo K, Maesaka JK, Fishbane S. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. *Kidney Int*. 2002;62:2202-2207.
- (18) Efrati S, Dishy V, Averbukh M, Blatt A, Krakover R, Weisgarten J, Morrow JD, Stein MC, Golik A. The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. *Kidney Int*. 2003;64:2182-2187.
- (19) El Mahmoud R, Le Feuvre C, Le Quan Sang KH, Helft G, Beygui F, Batisse JP, Metzger JP. [Absence of nephro-protective effect of acetylcysteine in patients with chronic renal failure investigated by coronary angiography]. *Arch Mal Coeur Vaiss*. 2003;96:1157-1161.
- (20) Ferrario F, Barone MT, Landoni G, Genderini A, Heidemperger M, Trezzi M, Piccaluga E, Danna P, Scorza D. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study. *Nephrol Dial Transplant*. 2009;24:3103-3107.
- (21) Fung JW, Szeto CC, Chan WW, Kum LC, Chan AK, Wong JT, Wu EB, Yip GW, Chan JY, Yu CM, Woo KS, Sanderson JE. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. *Am J Kidney Dis*. 2004;43:801-808.
- (22) Goldenberg I, Shechter M, Matetzky S, Jonas M, Adam M, Pres H, Elian D, Agranat O, Schwammenthal E, Guetta V. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. *Eur Heart J*. 2004;25:212-218.
- (23) Gomes VO, Poli de Figueredo CE, Caramori P, Lasevitch R, Bodanese LC, Araújo A, Röedel AP, Caramori AP, Brito FS Jr, Bezerra HG, Nery P, Brizolara A. N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial. *Heart*. 2005;91:774-778.
- (24) Gulel O, Keles T, Eraslan H, Aydogdu S, Diker E, Ulusoy V. Prophylactic acetylcysteine usage for prevention of contrast nephropathy after coronary angiography. *J Cardiovasc Pharmacol*. 2005;46:464-467.
- (25) Heng AE, Cellarier E, Aublet-Cuvelier B, Decalf V, Motreff P, Marcaggi X, Deteix P, Souweine B. Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date? *Clin Nephrol*. 2008;70:475-484.
- (26) Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, Fan K, Lee CH, Lam WF. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. *JAMA*. 2003 ;289:553-558.
- (27) Kefer JM, Hanet CE, Boitte S, Wilmotte L, De KM. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient? *Acta Cardiol*. 2003;58:555-560.

- (28) Kim BJ, Sung KC, Kim BS, Kang JH, Lee KB, Kim H, Lee MH. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial. *Int J Cardiol.* 2010;138:239-245.
- (29) Kimmel M, Butscheid M, Brenner S, Kuhlmann U, Klotz U, Alscher DM. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results. *Nephrol Dial Transplant.* 2008;23:1241-1245.
- (30) Kinbara T, Hayano T, Ohtani N, Furutani Y, Moritani K, Matsuzaki M. Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy. *J Cardiol.* 2010;55:174-179.
- (31) Kotlyar E, Keogh AM, Thavapalachandran S, Allada CS, Sharp J, Dias L, Muller D. Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures--a randomised controlled trial. *Heart Lung Circ.* 2005;14:245-451.
- (32) Lawlor DK, Moist L, DeRose G, Harris KA, Lovell MB, Kribs SW, Elliot J, Forbes TL. Prevention of contrast-induced nephropathy in vascular surgery patients. *Ann Vasc Surg.* 2007;21:593-597.
- (33) Loutrianakis E, Stella D, Hussain A et al. Randomized comparison of fenoldopam and N-acetylcysteine to saline in the prevention of radiocontrast induced nephropathy. *J Am Coll Cardiol.* 41, 327A. 2010.

Ref Type: Abstract

- (34) MacNeill BD, Harding SA, Bazari H, Patton KK, Colon-Hernandez P, DeJoseph D, Jang IK. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. *Catheter Cardiovasc Interv.* 2003;60:458-461.
- (35) Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbicchi F, Montorsi P, Veglia F, Bartorelli AL. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. *N Engl J Med.* 2006;354:2773-2782.
- (36) Miner SE, Dzavik V, Nguyen-Ho P, Richardson R, Mitchell J, Atchison D, Seidelin P, Daly P, Ross J, McLaughlin PR, Ing D, Lewycky P, Barolet A, Schwartz L. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. *Am Heart J.* 2004;148:690-695.
- (37) Moore NN, Lapsley M, Norden AG, Firth JD, Gaunt ME, Varty K, Boyle JR. Does N-acetylcysteine prevent contrast-induced nephropathy during endovascular AAA repair? A randomized controlled pilot study. *J Endovasc Ther.* 2006;13:660-666.
- (38) Nangung J, Doh JH, Lee SY, Lee WR. Effect of N acetylcysteine in the prevention of contrast induced nephropathy after coronary angiography. In: Abstracts of the 10th Annual Interventional Vascular Therapeutics Angioplasty Summit - Transcatheter Cardiovascular Therapeutics Asia Pacific Symposium. April 28-30, 2005, Seoul, Korea. *Am J Cardiol.* 95, 1A-83A. 2005.

Ref Type: Abstract

- (39) Ochoa A, Pellizzon G, Addala S, Grines C, Isayenko Y, Boura J, Rempinski D, O'Neill W, Kahn J. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention. *J Interv Cardiol.* 2004;17:159-165.
- (40) Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. *Am Heart J.* 2003;146:E23.

- (41) Rashid ST, Salman M, Myint F, Baker DM, Agarwal S, Sweny P, Hamilton G. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. *J Vasc Surg.* 2004;40:1136-1141.
- (42) Reinecke H, Fobker M, Wellmann J, Becke B, Fleiter J, Heitmeyer C, Breithardt G, Hense HW, Schaefer RM. A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial. *Clin Res Cardiol.* 2007;96:130-139.
- (43) Sadat U, Walsh SR, Norden AG, Gillard JH, Boyle JR. Does Oral N-Acetylcysteine Reduce Contrast-Induced Renal Injury in Patients With Peripheral Arterial Disease Undergoing Peripheral Angiography? A Randomized-Controlled Study. *Angiology.* 2011; 62:225-230.
- (44) Sandhu C, Belli AM, Oliveira DB. The role of N-acetylcysteine in the prevention of contrast-induced nephrotoxicity. *Cardiovasc Intervent Radiol.* 2006;29:344-347.
- (45) Seyon RA, Jensen LA, Ferguson IA, Williams RG. Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention. *Heart Lung.* 2007;36:195-204.
- (46) Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. *J Am Coll Cardiol.* 2002;40:1383-1388.
- (47) Sinha SK, Berry WA, Buetti J, Junaid A, Fine A, Krahn J. The prevention of radiocontrast-induced nephropathy trial (print): a prospective, double-blind, randomized, controlled trial of iso-osmolar versus low-osmolar radiocontrast in combination with N-acetylcysteine versus placebo [Abstract]. Presented at the American Heart Association Scientific Sessions, New Orleans, Louisiana, 7-10 November 2004. Ref Type: Abstract
- (48) Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, Fuernau G, Erbs S, Linke A, Diederich KW, Nowak M, Desch S, Gutberlet M, Schuler G. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate Percutaneous Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. *J Am Coll Cardiol.* 2010;55:2201-2219.
- (49) Vallero A, Cesano G, Pozzato M, Garbo R, Minelli M, Quarello F, Formica M. [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)]. *G Ital Nefrol.* 2002;19:529-533.
- (50) Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al Shamari A, Sutander A, Williams T, Fox RS, Levin A. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. *Am Heart J.* 2004 ;148:422-429.

아세틸시스테인은 조영제 유발 콩팥 손상을 예방하지 못한다

조 상 호 교수 한림대학교 성심병원 순환기내과

Summary

배경

Acetylcysteine이 조영제-유발 콩팥 손상(contrast-induced acute kidney injury, CIAKI)에 효과적인지는 확실하지 않다.

방법 및 결과

혈관 조영술을 시행 받으며, 최소한 1가지 이상의 CIAKI 위험인자(70세 이상의 연령, 신기능 저하, 당뇨병, 심부전, 저혈압)를 가진 총 2,308명의 환자를 acetylcysteine 군과 위약군으로 무작위 배정하였다. 배정은 central Web-base로 blinding하여 시행하였다. Acetylcysteine은 조영술 전후로 각각 2회씩 경구투여하였다. 모든 분석은 intention-to-treat 방법으로 시행하였다.

일차 목표점인 CIAKI의 발생은 acetylcysteine군에서 12.7%, 위약군에서 12.7%로 동일하였다(relative risk, 1.00; 95% CI, 0.81-1.25; $P=0.97$).

30일째 사망과 투석도 양군에서 동일하였다(각각 2.2%, 2.3%; HR, 0.97; 95% CI, 0.56-1.69; $P=0.92$). 신기능 저하자를 포함한 모든 하위군에서도 동일한 결과를 보였다.

결론

관상동맥 및 말초혈관 조영술을 시행 받는 고위험 환자를 대상으로 시행한 본 대규모 무작위 임상시험에서 acetylcysteine은 CIAKI와 임상 사건을 감소시키지 못하였다.

Commentary

CIAKI는 조영제를 이용한 모든 검사 및 시술에서 발생할 수 있으며, 최근 급속하게 증가하는 관상동맥 조영술 및 중재시술을 고려할 때 매우 중요한 질병이다. 대개 혈청 creatinine이 기저보다 25% 이상 증가하거나 0.5mg/dL 이상 증가하는 것으로 정의하며, 발생 시에는 장단기 사망 및 심혈관계 사건 발생의 주요 위험인자로 밝혀졌다. 따라서 이를 예방하기 위한 많은 노력이 이루어져 왔고, 가장 기본적으로는 조영제 사용 전후로 충분한 수액 사용이 권장되고 있다.¹ 그러나 여전히 CIAKI 위험이 존재하고 있어서 혈관확장제(칼슘차단제, fenoldopam, theophylline 등)를 비롯한 여러 약제가 시도되었으나 대개 큰 효과를 보이지 못하였고, 항산화제인 N-Acetylcysteine과 소변의 알칼리화를 목표로 하는 sodium bicarbonate가 논란이 있기는 하지만 현재 널리 사용되고 있는 실정이다.

N-Acetylcysteine은 대표적인 항산화제로 이전부터 거담제나 약물 중독환자에서 사용되어져 왔다. 2000년, Tepel 등에 의해서 최초로 CIAKI에 효과적임이 발표된 후에 수많은 연구가 이루어졌으나, 결과는 효과가 있다 또는 없다로 매우 상이하게 나타났으며, 여러 메타분석에서도 그 효과에 대한 대립되는 의견이 지속되었다.²⁻⁴

N-Acetylcysteine의 효과에 대한 이러한 상반된 연구 결과는 연구대상 집단의 다양성, CIAKI의 진단기준의 차이, 혈청 creatinine을 측정하는 기간의 차이 및 병용하는 수액요법의 다양함 등과 같이 여러 이유가 있을 수 있다.

소규모로 진행된 임상연구에서는 대개 효과가 있다는 결과를 보였고, 대규모 환자를 대상으로 한 연구에서는 그 효과가 미미하거나 전혀 없다고 보고하고 있다. 따라서 메타분석에서 상반되는 결과를 보인 것은 이러한 개별 연구들이 큰 heterogeneity를 보였기 때문이라고 할 수 있다. 이러한 측면에서 보다 확실하게

N-Acetylcysteine의 효과를 검증하기 위해서는 대규모 무작위배정 위약 대조군 임상시험이 필요한데, 본 연구가 바로 그러한 연구이며 시의 적절하게 해답을 제시하였다고 본다. 즉, N-Acetylcysteine은 CIAKI의 발생과 임상사건 감소에 효과가 없다는 결론을 내리고 있다.

몇몇 전문가들은 이 연구를 바탕으로 향후에 N-Acetylcysteine이 사용되지 않을 것이라 예상하고 있으나, 본인의 생각은 다르다. 즉, 이 약제가 가진 여러 장점인 적은 부작용, 낮은 가격, 쉽게 구할 수 있다는 점, 간단한 투여 방법을 고려한다면 추가 연구가 나올 때까지는 좀 더 기다리는 신중한 자세가 필요하지 않을까 한다. 즉, 이 연구만으로 CIAKI의 고위험 환자에서 N-Acetylcysteine 투여를 일괄적으로 중단할 필요는 없다고 생각한다. 본 ACT(Acetylcysteine for Contrast-Induced Nephropathy) 연구는 CIAKI의 가장 큰 위험인자인 기저 신기능 저하 환자가 생각보다 적었다는 점을 고려할 때, eGFR <60mg/dL 환자만을 대상으로 하는 대규모 연구가 필요하다.

References

1. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliquet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirllet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D. Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2010;31:2501-2555.
2. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. *N Engl J Med*. 2000;343:180-184.
3. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiochi F, Montorsi P, Veglia F, Bartorelli AL. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. *N Engl J Med*. 2006;354:2773-2782.
4. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. *Ann Intern Med*. 2008;148:284-294.

Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Coronary and Peripheral Vascular Angiography

Main Results From the Randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT)

ACT Investigators*

Background—It remains uncertain whether acetylcysteine prevents contrast-induced acute kidney injury.

Methods and Results—We randomly assigned 2308 patients undergoing an intravascular angiographic procedure with at least 1 risk factor for contrast-induced acute kidney injury (age >70 years, renal failure, diabetes mellitus, heart failure, or hypotension) to acetylcysteine 1200 mg or placebo. The study drugs were administered orally twice daily for 2 doses before and 2 doses after the procedure. The allocation was concealed (central Web-based randomization). All analysis followed the intention-to-treat principle. The incidence of contrast-induced acute kidney injury (primary end point) was 12.7% in the acetylcysteine group and 12.7% in the control group (relative risk, 1.00; 95% confidence interval, 0.81 to 1.25; $P=0.97$). A combined end point of mortality or need for dialysis at 30 days was also similar in both groups (2.2% and 2.3%, respectively; hazard ratio, 0.97; 95% confidence interval, 0.56 to 1.69; $P=0.92$). Consistent effects were observed in all subgroups analyzed, including those with renal impairment.

Conclusions—In this large randomized trial, we found that acetylcysteine does not reduce the risk of contrast-induced acute kidney injury or other clinically relevant outcomes in at-risk patients undergoing coronary and peripheral vascular angiography.

Clinical Trial Registration—<http://www.clinicaltrials.gov>. Unique identifier: NCT00736866.

(*Circulation*. 2011;124:1250-1259.)

Key Words: acute kidney injury ■ coronary angiogram ■ contrast media ■ angioplasty ■ acetylcysteine

Contrast-induced acute kidney injury represents a serious complication of procedures requiring administration of iodinated contrast media and is associated with the need for dialysis, prolonged hospitalization,^{1–3} increased costs, and mortality.^{4,5}

Clinical Perspective on p 105

Acetylcysteine may prevent contrast-induced acute kidney injury by diminishing direct oxidative stress and by improving renal hemodynamics.^{6–8} It also represents a safe, inexpensive, and easily administered intervention. Since the first randomized trial testing acetylcysteine for the prevention of contrast-induced acute kidney injury was published,⁹ several trials were completed and reached inconsistent results.¹⁰ Such studies are limited by low statistical power (the median study size considering all previous trials was 80 patients), and most failed to meet quality standards such as allocation conceal-

ment, blinding, and intention-to-treat analysis.¹⁰ Systematic reviews have found high heterogeneity across studies, precluding definitive conclusions regarding the efficacy of acetylcysteine.^{10–16} Current guidelines disagree on whether acetylcysteine should be recommended for high-risk patients, although all recognize that more data are required.^{17–20}

The conflicting results of previous evidence have left clinicians uncertain about the effectiveness of acetylcysteine, and several specialists highlighted the need for a large-scale trial to inform clinical practice.^{13,21,22} To address this issue, we conducted the Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT), a multicenter randomized trial of acetylcysteine in patients at risk for contrast-induced acute kidney injury undergoing angiography.

Methods

Trial Design

ACT was an academic pragmatic randomized (concealed) controlled trial of acetylcysteine versus placebo in patients at risk for contrast-

Received April 19, 2011; accepted June 28, 2011.

*A complete list of the members of the ACT Investigators appears in the Acknowledgments at the end of the article.

From Research Institute, Hospital do Coração, São Paulo, Brazil. See Acknowledgments for a complete list of affiliations and locations.

The online-only Data Supplement is available with this article at <http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.111.038943/-/DC1>.

Correspondence to Dr Otavio Berwanger, Research Institute, Hospital do Coração (HCor), Rua Abílio Soares 250, 12th Floor, CEP: 04005-000, São Paulo SP, Brazil. E-mail oberwanger@hcor.com.br

© 2011 American Heart Association, Inc.

Circulation is available at <http://circ.ahajournals.org>

DOI: 10.1161/CIRCULATIONAHA.111.038943

induced acute kidney injury undergoing an intravascular angiographic procedure conducted in 46 sites in Brazil. Participants, healthcare staff, data collectors, and outcome assessors were blinded to whether patients received acetylcysteine or placebo. All analyses followed the intention-to-treat principle. The trial was designed by the steering committee. A detailed description of the study design has been published previously,²³ and the trial was registered at <http://www.clinicaltrials.gov> (NCT00736866). The study was approved by the research ethics board of each participating institution.

Study Population

Patients undergoing coronary or peripheral arterial diagnostic intravascular angiography or percutaneous intervention were eligible for the trial if they had at least 1 risk factor for contrast-induced acute kidney injury: age >70 years, chronic renal failure (stable serum creatinine concentrations >132.6 $\mu\text{mol/L}$ [1.5 mg/dL]), diabetes mellitus, clinical evidence of congestive heart failure, left ventricular ejection fraction <0.45, or hypotension. We chose the inclusion criteria on the basis of independent risk factors validated by previous observational studies.^{24,25} We excluded patients on dialysis and those with ST-segment elevation myocardial infarction undergoing primary angioplasty (because they were unable to receive the study hydration protocol for at least 6 hours before the procedure). Women were excluded if they were pregnant, breastfeeding, or aged <45 years and did not use contraceptive methods.

Randomization

After providing written informed consent, patients were randomized in a 1:1 ratio to receive acetylcysteine or placebo. The allocation list was generated in random permuted blocks of variable size (4, 6, 8, or 10) and was stratified by site. To guarantee concealment of the allocation list, randomization was implemented through a 24-hour Web-based automated randomization system.

Study Interventions

The study drugs were packed in identical envelopes containing either 600 mg of oral powder acetylcysteine (Medley, Brazil) or placebo to be diluted in water. The powder and the solution were identical in appearance, taste, and smell. A dose of 1200 mg (2 envelopes) of acetylcysteine or placebo was administered orally every 12 hours, for 2 doses before and 2 doses after the procedure. All decisions about management of patients were at the discretion of the medical team, except that nontrial acetylcysteine was not allowed.

Hydration with 0.9% saline, 1 mL/kg per hour, from 6 to 12 hours before to 6 to 12 hours after angiography, was strongly recommended. However, changes in the total volume or speed of administration were permitted.

Study Procedures

Data were obtained at baseline, on the day of the angiography, and between 48 to 96 hours and at 30 days after angiography. Baseline data were collected immediately after randomization and before administration of hydration scheme and the study drugs. Data collected at baseline included demographic and clinical characteristics and the most recent serum creatinine level measured within the past 3 months under stable clinical conditions. On the day of the angiography, we collected data regarding the administration of the study drug, hydration scheme, and angiographic procedure. Between 48 to 96 hours after angiography, we assessed vital status, need for dialysis, need for another angiogram, and data regarding the administration of the study drugs and hydration and collected a blood sample for serum creatinine measurement. However, we strongly recommended to all investigators that the creatinine sample be collected within a 48- to 72-hour interval. Whenever >1 measurement was available during the period of 48 to 96 hours, the measure closer to 72 hours was used. We contacted the patients 30 days after the angiography to assess the need for dialysis and the vital status.

End Points

The primary end point was contrast-induced acute kidney injury, defined as a 25% elevation of serum creatinine above baseline between 48 and 96 hours after angiography. The secondary end points were as follows: a composite of death or need for dialysis in 48 to 96 hours and at 30 days; individual components of the composite outcome; elevation $\geq 44.2 \mu\text{mol/L}$ (0.5 mg/dL) in serum creatinine between 48 and 96 hours; cardiovascular deaths at 30 days; and other adverse events. Elevation $\geq 13.3 \mu\text{mol/L}$ (0.3 mg/dL) in serum creatinine, the Acute Kidney Injury Network criteria for acute kidney injury, was a post hoc defined end point.²⁶

Trial Management

The coordinating center resources included procedures manuals, slide sets, and a study Web site. Trained investigators and study coordinators at each site collected the data using a Web-based system. Data quality control was guaranteed by automated data entry checks, weekly contact with investigators, on-site monitoring, and central statistical monitoring.²⁷ General feedback was provided at investigators' meetings and in periodic newsletters.

Sample Size

On the basis of a recent meta-analysis, we anticipated an incidence of contrast-induced acute kidney injury at 48 to 96 hours of $\approx 15\%$.¹⁰ To detect a 30% relative risk reduction, with 90% statistical power and a 2-tailed α of 5%, we sought to include 2300 patients.

Statistical Analysis

All analyses were performed on an intention-to-treat basis, and no postrandomization exclusions were performed. Differences in discrete variables were evaluated by the χ^2 test. Continuous variables with skewed distributions were analyzed with the Wilcoxon rank sum test. The results of comparisons of proportions are presented as relative risks and their respective 95% confidence intervals (CIs). Secondary outcomes evaluated 30 days after randomization were analyzed with unadjusted Cox proportional hazards regression. The composite outcome death or need for dialysis was presented as Kaplan-Meier curves. Missing values were not imputed.

A subgroup effect was inferred when the χ^2 test for homogeneity of effects was statistically significant. The following prespecified subgroups were analyzed: age >70 or ≤ 70 years, gender, patients with or without previous renal failure (serum creatinine >132.6 $\mu\text{mol/L}$ [1.5 mg/dL]), presence of diabetes mellitus, and volume of contrast ≥ 140 mL. Subgroups were defined post hoc according to the following: time of measurement of creatinine after angiography, presence of acute coronary syndrome, type of contrast, and estimated glomerular filtration rate.

We conducted a prespecified random-effects meta-analysis to evaluate the results of the ACT in the context of previous randomized controlled trials of acetylcysteine versus placebo for preventing contrast-induced acute kidney injury (see additional methods in the online-only Data Supplement).²⁸ Because several systematic reviews addressing the same question were published to date, we screened references from previous reviews. This strategy was complemented by a comprehensive search on MEDLINE (2008 to present). The terms included in the electronic search were *contrast-induced nephropathy* combined with a sensitive strategy for the identification of randomized controlled trials.²⁹ We placed no language or publication status restrictions. We screened reference lists of all available primary studies and review articles to identify additional relevant citations. We found high heterogeneity between included trials. Thus, in an attempt to explain the high heterogeneity between trials, as a post hoc decision, we conducted stratified analyses according to prespecified methodological characteristics.

Statistical analyses were performed with the use of STATA/SE 10.0 (STATA Corp LP, College Station, TX) and SPSS release 16.0.2 (SPSS Inc, Chicago, IL).




Figure 1. Randomization, study drug adherence, and follow-up of the study patients.

Results

Study Participants

Between September 2008 and July 2010, a total of 2308 patients were enrolled in 46 sites in Brazil: 1172 patients were allocated to acetylcysteine and 1136 to placebo (Figure 1). A follow-up serum creatinine was not collected in 19 patients (1.6%) in the acetylcysteine group and in 17 patients (1.5%) in the placebo group. Information for outcomes at 30 days was available for all but 2 patients (99.9% with complete follow-up).

The baseline characteristics were well balanced between the groups (Table 1). The most common reasons for inclusion were diabetes mellitus, which was present in 1395 patients (60.4%), and age >70 years in 1202 patients (52.1%). Approximately half of the patients (1138) had an estimated creatinine clearance <60 mL/min (1 mL/s), and 35.4% of the sample was included during an acute coronary syndrome episode.

Compliance With Study Protocol and Characteristics of Angiography

From all of the included patients, 67.2% underwent diagnostic coronary angiographies, 28.8% were submitted to percutaneous coronary interventions, and 2.8% were submitted to peripheral vascular angiography (Table 2). Twenty-seven patients (1.2%) had their angiography cancelled after randomization but were kept in the analysis according to the intention-to-treat principle. Low-osmolality contrast medium was the most common type of contrast used (74.7% of the cases). In approximately half of the included patients, the volume of contrast administered was >100 mL.

Compliance with all 4 study drug doses was >95%, and <1% of the patients did not receive the study drugs before angiography (Figure 1). Ninety-eight percent of the patients received intravenous hydration before and 98.0% after the procedure (Table 2). The median duration of hydration was 6 hours before and after angiography for both groups.

The mean times between angiography and follow-up serum creatinine sampling were 57.6 ± 16.9 and 58.2 ± 16.9 hours for

the acetylcysteine and placebo groups ($P=0.48$), respectively. For most patients (76.4%), serum creatinine was collected between 48 and 72 hours after angiography (Table 2).

End Points

The primary end point occurred in 147 of 1153 patients (12.7%) in the acetylcysteine group and in 142 of 1119 patients (12.7%) in the placebo group (relative risk, 1.00; 95% CI, 0.81 to 1.25; $P=0.97$) (Table 3). Results were similar when only patients ultimately submitted to angiography were considered: 144 of 1142 (12.6%) and 140 of 1111 (12.6%) patients in the acetylcysteine and placebo groups, respectively (relative risk, 1.00; 95% CI, 0.81 to 1.24; $P=0.99$). Elevation of $\geq 44.2 \mu\text{mol/L}$ (0.5 mg/dL) in creatinine after the procedure was similar between groups (relative risk, 1.04; 95% CI, 0.69 to 1.57; $P=0.85$). Doubling of creatinine was also similar in both groups (relative risk, 0.74; 95% CI, 0.36 to 1.52; $P=0.41$).

The incidence of the composite outcome death or need for dialysis at 30 days was 2.2% in the acetylcysteine group and 2.3% in the placebo group (hazard ratio, 0.97; 95% CI, 0.56 to 1.69; $P=0.92$) (Table 3 and Figure 2). The incidence of the composite outcome death, need for dialysis, or doubling in serum creatinine, as well as the incidence of the individual components of this composite outcome, was not statistically different between the acetylcysteine and placebo groups. Cardiovascular deaths at 30 days were similar between the experimental and control groups (hazard ratio, 0.99; 95% CI, 0.51 to 1.90; $P=0.97$). There was also no difference between groups for outcomes defined post hoc.

Subgroup Analysis

Effects on Patients With Impaired Renal Function

There was no effect of acetylcysteine in the 367 patients with baseline serum creatinine $>132.6 \mu\text{mol/L}$ (1.5 mg/dL) (acetylcysteine group: 12/188 and placebo group: 10/179; $P=0.75$ for homogeneity of effects) or in the 823 patients with estimated glomerular filtration rate between 30 and 60 mL/min per 1.73 m^2 (acetylcysteine group: 30/425 and

Table 1. Baseline Characteristics of Patients

Characteristic	Acetylcysteine (n=1172)	Placebo (n=1136)
Female sex, No. (%)	445 (38.0)	447 (39.3)
Age, mean±SD, y	68.0±10.4	68.1±10.4
Patients fulfilling inclusion criteria		
Serum creatinine >132.6 μmol/L (1.5 mg/dL), No. (%)	180 (15.4)	182 (16.0)
Diabetes mellitus, No. (%)	717 (61.2)	678 (59.7)
Known heart failure, No. (%)	116 (9.9)	104 (9.2)
Hypotension, No. (%)	3 (0.3)	2 (0.2)
Age >70 y, No. (%)	601 (51.3)	601 (52.9)
Acute coronary syndrome, No. (%)	419 (35.8)	397 (34.9)
History of hypertension, No. (%)	1,014 (86.5)	976 (85.9)
Previous medication		
Use of NSAIDs >7 d, No. (%)	63 (5.4)	59 (5.2)
Use of ACE inhibitor, No. (%)	698 (59.6)	661 (58.2)
Use of diuretics, No. (%)	442 (37.7)	401 (35.3)
Use of metformin, No. (%)	362 (30.9)	336 (29.6)
Serum creatinine, mg/dL	1.2±0.5	1.2±0.5
Estimated creatinine clearance, mL/min*		
Mean±SD	67.6±31.4	67.7±32.1
<30 mL/min, No. (%)	68 (5.8)	63 (5.5)
30 to 60 mL/min, No. (%)	515 (43.9)	492 (43.3)
>60 mL/min, No. (%)	589 (50.3)	581 (51.2)
Estimated glomerular filtration rate, mL/min per 1.73 m ² †		
Mean±SD	69.3±28.7	69.0±27.9
<30 mL/min, No. (%)	58 (4.9)	50 (4.4)
30 to 60 mL/min, No. (%)	428 (36.5)	404 (35.6)
>60 mL/min, No. (%)	686 (58.5)	682 (60.0)
Weight, mean±SD, kg	73.1±13.9	73.3±14.7

NSAID indicates nonsteroidal anti-inflammatory drug; ACE, angiotensin-converting enzyme. There was no statistically significant difference for baseline characteristics.

*Creatinine clearance estimated by the Cockcroft-Gault formula.

†Glomerular filtration rate estimated by the abbreviated Modification of Diet in Renal Disease study equation.

placebo group: 27/398) or <30 mL/min per 1.73 m² (acetylcysteine group: 6/56 and placebo group: 3/48; $P=0.73$ for homogeneity of effects), as shown in Figure 3.

Effects on Other Subgroups

The neutral effect of acetylcysteine on the risk of contrast-induced acute kidney injury was also consistent in those with or without diabetes mellitus ($P=0.42$) and across other subgroups such as patients aged >70 or ≤70 years ($P=0.52$), male or female patients ($P=0.55$), or exposure to high (≥140 mL) or low (<140 mL) volumes of contrast media ($P=0.79$), as shown in Figure 3. There was no effect of acetylcysteine in the subgroup of patients who had serum creatinine collected within 48 to 72 hours after angiography or in the subgroup in which serum creatinine was collected between 72 and 96 hours ($P=0.36$).

Table 2. Procedure Characteristics, Protocol Adequacy, and Hydration Scheme

Characteristic	Acetylcysteine (n=1172)	Placebo (n=1136)	<i>P</i>
Procedure, No. of patients/total No. (%)			0.79
Peripheral vascular angiography	32 (2.7)	32 (2.8)	
Coronary diagnostic angiography	778 (66.4)	774 (68.1)	
Percutaneous coronary intervention	347 (29.6)	318 (28.0)	
Not submitted to angiography	15 (1.3)	12 (1.1)	
Adherence to study drug, No. of patients/total No. (%)			
Dose 1	1160 (99.0)	1128 (99.3)	0.28
Dose 2	1136 (96.9)	1099 (96.7)	0.61
Dose 3	1129 (96.3)	1090 (95.9)	0.71
Dose 4	1120 (95.5)	1076 (94.7)	0.39
Hydration before procedure, No. of patients/total No. (%)			
NaCl or bicarbonate	1147 (97.9)	1119 (98.5)	0.25
NaCl 0.9%, 1 mL/kg per hour for 6 h	552 (47.1)	540 (47.5)	0.83
NaCl 0.9%, any scheme	1090 (93.0)	1071 (94.3)	0.21
NaCl 0.45%	3 (0.2)	0 (0.0)	0.25*
Bicarbonate 0.9%	60 (5.1)	52 (4.6)	0.55
Duration of hydration before procedure, h			
Median (interquartile range)	6 (4–6)	6 (4–6)	0.32
Hydration after procedure, No. of patients/total No. (%)			
NaCl or bicarbonate	1145 (97.7)	1115 (98.2)	0.53
NaCl 0.9%, 1 mL/kg per hour for 6 h	814 (69.4)	792 (69.7)	0.92
NaCl 0.9%, any scheme	1129 (96.3)	1100 (96.8)	0.58
NaCl 0.45%	1 (0.08)	0 (0)	1.00*
Bicarbonate 0.9%	66 (5.6)	62 (5.5)	0.85
Duration of hydration after procedure, h			
Median (interquartile range)	6 (6–6)	6 (6–6)	0.71
Contrast type, No. (%)†			
High osmolarity	253 (21.9)	256 (22.8)	0.86
Low osmolarity	869 (75.1)	836 (74.4)	
Iso-osmolar	35 (3.0)	32 (2.8)	
Contrast volume, mL			
Median (interquartile range)	100 (70–130)	100 (70–130)	0.66
Additional angiography within 48–96 h after first procedure, No. (%)	38 (3.2)	47 (4.1)	0.25

(Continued)

Table 2. Continued

Characteristic	Acetylcysteine (n=1172)	Placebo (n=1136)	P
Timing of serum creatinine sampling after angiography, No. (%)‡			0.87
48 to ≤72 h	876 (76.3)	851 (76.6)	
72 to 96 h	272 (23.7)	260 (23.4)	

*Fisher exact test.

†In the acetylcysteine and placebo groups, 1157 and 1124 patients, respectively, were ultimately submitted to angiography. These are the denominators for type of contrast.

‡Serum creatinine after angiography was available for 1148 and 1111 patients in the acetylcysteine and placebo groups, respectively.

Adverse Events

The incidence of other serious adverse events was 1.3% in the acetylcysteine group and 2.2% in the placebo group ($P=0.09$) (Table I in the online-only Data Supplement). There was no difference between the study groups for any other adverse events, except that vomiting was less common in the acetylcysteine than in the placebo group (0.3% and 1.2%, respectively; $P=0.02$).

Updated Meta-Analysis

We identified 46 randomized controlled trials comparing acetylcysteine with placebo (or no acetylcysteine) in patients undergoing cardiac or peripheral angiography (Table II in the online-only Data Supplement). One study was excluded from our meta-analyses because no cases of contrast-induced acute kidney injury were observed in either the treatment or control group.³⁰ There was important heterogeneity between studies ($P<0.0001$; $I^2=59\%$). Therefore, we did not combine the results of all studies but instead attempted to identify the sources of heterogeneity by stratifying the analyses according to methodological characteristics of the trials.




Figure 2. Probability of death or need for dialysis from the day of randomization (day 0) to day 30 among patients in the acetylcysteine and placebo groups.

The pooled relative risk in studies with unclear or inadequate allocation concealment was 0.59 (95% CI, 0.43 to 0.82), with substantial heterogeneity across trials ($I^2=57\%$), whereas in studies with allocation concealment, the effect estimate (relative risk, 1.01; 95% CI, 0.75 to 1.37) was similar to that found in our study, with no remaining heterogeneity ($I^2=0\%$) (Figure 4). Meta-analyses stratified according to adequacy of all methodological characteristics (allocation concealment, double blinding, and intention-to-treat analysis) revealed a similar pattern. The pooled relative risk for low-quality studies was 0.63 (95% CI, 0.47 to 0.85; $I^2=56\%$) and for studies meeting all 3 methodological criteria was 1.05 (95% CI, 0.73 to 1.53; $I^2=0\%$).

Discussion

In this large randomized trial, acetylcysteine did not reduce the incidence of contrast-induced acute kidney injury. Acetylcysteine also did not show statistically sig-

Table 3. End Points

Outcomes	Acetylcysteine	Placebo	Relative Risk (95% CI)	P
Primary end point, No. of events/total No. (%)				
Contrast-induced acute kidney injury	147/1153 (12.7)	142/1119 (12.7)	1.00 (0.81–1.25)	0.97
Other end points, No. of events/total No. (%)				
End points in 48 to 96 h				
Doubling in serum creatinine	13/1153 (1.1)	17/1119 (1.5)	0.74 (0.36–1.52)	0.41
Elevation $\geq 44.2 \mu\text{mol/L}$ (0.5 mg/dL) in serum creatinine	45/1153 (3.9)	42/1119 (3.8)	1.04 (0.69–1.57)	0.85
Elevation $\geq 13.3 \mu\text{mol/L}$ (0.3 mg/dL) in serum creatinine	140/1153 (12.1)	123/1119 (11.0)	1.10 (0.88–1.39)	0.39
End points at 30 d				
Deaths or need for dialysis*	26/1171 (2.2)	26/1135 (2.3)	0.97 (0.56–1.69)	0.92
Death, need for dialysis, or doubling in serum creatinine	38/1171 (3.2)	41/1135 (3.6)	0.90 (0.58–1.39)	0.63
Deaths*	23/1171 (2.0)	24/1135 (2.1)	0.97 (0.54–1.73)	0.92
Need for dialysis*	3/1171 (0.3)	3/1135 (0.3)	0.87 (0.17–4.35)	0.86
Cardiovascular deaths*	18/1171 (1.5)	18/1135 (1.6)	0.99 (0.51–1.90)	0.97

CI indicates confidence interval.

*Results are hazard ratios with 95% CI and P values obtained by Cox regression.




Figure 3. Effect of acetylcysteine on contrast-induced acute kidney injury according to subgroup. CI indicates confidence interval; eGFR, estimated glomerular filtration rate.

nificant beneficial effects on other end points such as all-cause mortality and need for dialysis at 30 days. These results were consistent among all subgroups evaluated, including higher-risk patients such as those with renal failure, those with diabetes mellitus, and those who received the largest amounts of contrast.

Several strengths of the ACT reinforce our findings. It represents the largest trial testing the effects of acetylcysteine

for the prevention of contrast-induced acute kidney injury conducted to date. Although the incidence of contrast-induced acute kidney injury observed in the control group (12.7%) was somewhat lower than anticipated in our sample size calculation (15%), still the ACT would have adequate statistical power (84%) to detect a 30% decrease in the risk of contrast-induced acute kidney injury. We sought to ensure adequate methodological quality by using concealed random-




Figure 4. Meta-analyses of randomized controlled trials of acetylcysteine for preventing contrast-induced acute kidney injury stratified according to methodological criteria and the Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT) main result. I² represents the percentage of total variation across studies due to heterogeneity rather than chance. We considered all methodological criteria adequate when a trial had allocation concealment and was blinded and the analysis followed the intention-to-treat principle. CI indicates confidence interval; NA, not applicable.

ization; blinding patients, investigators, caregivers, and outcome assessors; analyzing data according to the intention-to-treat principle; and by having >98% of patients with complete follow-up data. We tested a high dose of acetylcysteine because previous evidence suggested that a dose of 1200 mg twice daily may be superior to a dose of 600 mg twice daily.^{16,31} Compliance to the study drugs was >95%, and cointerventions were well balanced between the groups. We used different methods to guarantee data quality including on-site monitoring, central statistical monitoring of the data, and data collection through a Web-based electronic data capture system.

More than 40 acetylcysteine trials have been completed in the past 10 years and have reached inconsistent results. One plausible explanation for the contradictory findings may be related to methodological quality.^{11,12,15} In this regard, our meta-analysis of smaller high-quality studies published before the ACT found neutral effects of acetylcysteine for the prevention of contrast-induced acute kidney injury with no heterogeneity between studies. On the other hand, the meta-analysis of trials with inadequate methodology suggested a beneficial effect of this intervention but with important between-trial heterogeneity. These results are in accordance with previous empirical evidence suggesting that trials with inadequate or unclear concealment of allocation or unclear description on blinding tend to overestimate the treatment effects.^{32,33} The ACT confirms the findings of smaller high-quality studies and, together with them, provides consistent evidence to support the lack of effect of acetylcysteine for the prevention of contrast-induced acute kidney injury.

Differences between the ACT and previous studies should be noted. Although some trials have enrolled only patients with renal failure, our trial sought to test the effects of acetylcysteine over a broader population at risk for contrast-induced acute kidney injury.^{17–19} In this regard, besides renal failure, our patients were selected on the basis of other well-established independent risk factors such as age >70 years, diabetes mellitus, and heart failure.^{2,3,24,25} The adoption of such broad inclusion criteria did not result in a low-risk population, as indicated by an overall incidence of contrast-induced acute kidney injury close to 13%, which was consistent among subgroups and similar to the incidence of previous trials, as shown in a previous systematic review.¹⁰ Moreover, patients with diabetes mellitus or with renal impairment represented >70% of our sample, and approximately half of our patients had a creatinine clearance <60 mL/min (1 mL/s). Thus, our higher-risk subgroups had a larger sample size representation than the previous studies. Finally, we did not find evidence of a subgroup effect in higher-risk patients. In particular, there was no effect of acetylcysteine in the subgroup of 367 patients with baseline serum creatinine >132.6 $\mu\text{mol/L}$ (1.5 mg/dL) or in the subgroups with estimated glomerular filtration rate <60 mL/min per 1.73 m² (total of 927 patients). Although the power to draw definitive conclusions for any of the subgroups is low, in all subgroups the results were very consistent. Therefore, it is unlikely that a beneficial effect exists for any subgroup. Although most of the previous studies tested oral acetylcysteine, as we did in the ACT, some employed

intravenous formulations.^{34–36} Even so, it is unlikely that the choice of intravenous instead of oral administration of acetylcysteine would influence our results. In this sense, the largest study using intravenous acetylcysteine also reached neutral results.³⁶

Our trial has limitations. First, we did not observe a large number of events that allowed us to assess the effects of acetylcysteine on end points such as mortality and need for dialysis. However, despite the wide CIs, the point estimates for these outcomes showed neutral effects of acetylcysteine. Second, we used creatinine as our marker of kidney injury, and some recent publications suggest that newer markers such as cystatin C are more reliable for detecting contrast-induced acute kidney injury.^{37,38} Nevertheless, results based on creatinine measures were consistent with those observed for other clinical end points. Additionally, a cystatin C ACT substudy involving >150 patients has now been completed, and the results should be available soon. Third, the median volume of contrast used was low (100 mL), and previous studies demonstrated an association between contrast volume and risk of contrast-induced acute kidney injury.^{2,24} However, we found no evidence of a subgroup effect in patients who received >140 mL of contrast. Fourth, cointerventions other than hydration were at the discretion of the attending physician. Nevertheless, they were well balanced between groups. Fifth, we used a definition for contrast-induced acute kidney injury (25% elevation of serum creatinine from baseline) that may have high sensitivity but lack specificity. However, this definition has been used by most trials in the field.¹³ Furthermore, previous studies demonstrated that even such minor increases predict a higher mortality and morbidity.^{2,5} In addition, we found no effect of acetylcysteine when considering other definitions of contrast-induced acute kidney injury, such as a 100% or a 44.2- $\mu\text{mol/L}$ (0.5-mg/dL) increase in serum creatinine, although the incidence of contrast-induced acute kidney injury and the study power are smaller with those definitions.

Studies have demonstrated persistence of contrast media up to 7 days after angiography in patients with contrast-induced acute kidney injury.^{39,40} In this study, patients received acetylcysteine every 12 hours, 2 doses before and 2 doses after angiography. Thus, it may be suggested this was not a long enough duration of therapy. Nonetheless, we believe that extending acetylcysteine therapy would not change the results of our trial because the peak of renal dysfunction occurs shortly after angiography (2 to 5 days), with fast normalization after it.^{41,42} Furthermore, previous trials that suggested acetylcysteine to be effective administered the drug for only up to 48 hours after angiography.^{9,34,43}

In conclusion, our trial showed that acetylcysteine did not result in a lower incidence of contrast-induced acute kidney injury or other renal outcomes. On the basis of our results, we do not recommend routine use of acetylcysteine for patients undergoing angiography. These findings have important implications for clinical practice and may prevent unnecessary procedure delays and health expenditures associated with the administration of acetylcysteine.

Acknowledgments

We are indebted to all of the study coordinators, investigators, and patients who participated in the ACT. Participants in the ACT are as follows: **Writing Committee:** From Research Institute, Hospital do Coração, São Paulo, Brazil: Otávio Berwanger, Alexandre B. Cavalcanti, Amanda G.M.R. Sousa, Anna M. Buehler, Alessandra A. Kodama, Mariana T. Carballo, Vitor O. Carvalho, Celso Amodeo, Leda D. Lotaif, José Eduardo Sousa. From Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil: Amanda G.M.R. Sousa. **Statistical Analyses:** Mariana T. Carballo, Elivane S. Victor. **Trial Steering Committee:** Otávio Berwanger (chair), Alexandre B. Cavalcanti, Amanda G.M.R. Sousa, José Eduardo Sousa, Celso Amodeo, Leda D. Lotaif. **Trial Management Team:** Otávio Berwanger (chief investigator), Alexandre B. Cavalcanti (project manager), Anna M. Buehler (project manager), Mariana T. Carballo (statistician), Alessandra A. Kodama (data management), Eliana Santucci (research coordinator), Carlos E. S. Cardoso (data management), Dalmo da Silva (data management), Adailton L. Mendes (senior computer programmer), José Lobato (chief computer programmer). **Investigator Sites:** *Associação Hospital de Bauru*, Bauru, São Paulo: G. Prates, H. Yokoyama, P. Almeida, C. Pessoa; *Cardiocenter Hospital Santa Paula*, João Pessoa, Paraíba: H. Martins, M. Lopes, M. Barros; *Fundação Pública Estadual Hospital Gaspar Vianna*, Belém, Pará: H. Reis, C. Cordeiro; *Hospital Bandeirantes*, São Paulo: H. Castello, M. Cantarelli, S. Ferreira; *Hospital Barra Dor*, Rio de Janeiro: C. Mattos, M. Rati, C. Medeiros; *Hospital Beneficência Portuguesa*, São Paulo: J.A. Mangione, M.F. Mauro, S.A. Cristóvão, N.M. Carnieto, L.C. Rocha, D.F. Maksud, C. Barbosa; *Hospital Cardiologico Constantini*, Curitiba, Paraná: C. Costantini, S. Tarbine, M. Santos, C. Ortiz, A. Souza; *Hospital Copa Dor*, Rio de Janeiro: C. Mattos, L. Duarte; *Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo*, Ribeirão Preto, São Paulo: J. Marin Neto, G. Figueiredo, D. Lemos, F. Braga, G. Novaes, F. Oliveira, M. Tonani; *Hospital das Clínicas da Faculdade Federal de Pernambuco*, Recife, Pernambuco: E. Victor Filho, E. Rocha; *Hospital de Terapia Intensiva HTI*, Teresina, Piauí: P. Nunes, A. Sá Filho, I. Lima; *Hospital do Coração de Juiz de Fora*, Juiz de Fora, Minas Gerais: A. Muniz, J. Loures, A. Abraão; *Hospital do Coração de São Paulo*, São Paulo: J. Sousa, A. Moreira; *Hospital do Coração do Brasil*, Brasília, Distrito Federal: E. Araújo, L. Sousa, A. Fonseca; *Hospital Escola Álvaro Alvim*, Campos, Rio de Janeiro: J. Soares, C. Cunha; *Hospital Felício Rocho*, Belo Horizonte, Minas Gerais: J. Saad, F. Câmara, E. Falcheto; *Hospital Maternidade e Pronto Socorro Santa Lúcia*, Poços de Caldas, Minas Gerais: R. Berço, F.T.C. Dall'Orto, R. Almeida, R. Mendes; *Hospital Moinhos de Vento*, Porto Alegre, Rio Grande do Sul: M. Wainstein, J. Ribeiro, C. Teixeira; *Hospital Quinta Dor*, Rio de Janeiro: C. Mattos; *Hospital Regional do Sul de Minas*, Varginha, Minas Gerais: F. Cunha; F.T.C. Dall'Orto, J. Lisboa, D. Osugui; *Hospital Samaritano*, São Paulo: F. Stella, J. Almeida, A. Stella, F. Assunção, S. Souza, J. Malachia, P. Buononato; *Hospital Santa Catarina*, Blumenau, Santa Catarina: D. Zappi, M. Linhares, M. Junckes; *Hospital Santa Helena São Francisco Cardio Vida*, Aparecida de Goiânia, Goiás: J. Guimarães, D. Araújo Filho; *Hospital Santa Lucinda*, Sorocaba, São Paulo: J. Maiello, E. Seixas; *Hospital Santa Marcelina*, São Paulo: B. Almeida, B. Janella, M. Almeida; *Hospital São José do Avaí*, Itaperuna, Rio de Janeiro: A. Silva, A. Marco, A. Teixeira, J. Pinto; *Hospital SOS Cardio*, Florianópolis, Santa Catarina: L. São Thiago, L. Giuliano, F. Aranha, D. Arante; *Hospital UDI*, São Luís, Maranhão: M. Barbosa, F. Aguiar Filho, C. Gama; *Hospital Universitário São José*, Belo Horizonte, Minas Gerais: C. Arêas, M. Lacerda, I. Freitas, F.T.C. Dall'Orto; *INCOR Hemocardio*, Natal, Rio Grande do Norte: L.A. Oliveira, I.R. Oliveira, F. Pinheiro, C. Amaral; *INCORPI Hospital Fornecedores de Cana*, Piracicaba, São Paulo: L. Gubolino, P. Teixeira, J.F. Toledo; *Instituto Dante Pazzanese de Cardiologia*, São Paulo: A. Sousa, F. Feres, M. Centemero, J.R. Costa, V. Esteves, J. Polacini, R. Viana; *Instituto de Cardiologia*, São José, Santa Catarina: L. São Thiago, L. Giuliano, M. Antunes, R. Conceição; *Instituto de Cardiologia RGS Fundação Universitária de Cardiologia*, Porto Alegre, Rio Grande do Sul: A. Azmus, A. Quadros; *Instituto de Clínicas e Cirurgia de Juiz de Fora Hospital*

Monte Sinai, Juiz de Fora, Minas Gerais: G. Ramalho, R. Santos; *Instituto de Moléstias Cardiovasculares*, São José do Rio Preto, São Paulo: P. Garzon, D. Faria, C. Queirantes, P. Galeazzi, V. Cavallini, R. Carvalho; *Instituto do Coração do Triângulo Mineiro*, Uberlândia, Minas Gerais: R. Botelho, C. Rosa, M. Seabra, A. Pereira, S. Reis, V. Pereira, S. Cunha, P. Vitor; *Instituto do Coração de Taguatinga Hospital Anchieta*, Taguatinga, Distrito Federal: P. Motta, E. Osterne, F. X. Souza, V. Motta, M.S. Heleno, K.M. Ramalho; *Instituto Nacional de Cardiologia Laranjeiras*, Rio de Janeiro: H. Cramer, B. Santos Júnior, B. Tura, D. Cook, D. Justen; *Natal Hospital Center*, Natal, Rio Grande do Norte: M. Paiva, E. Czoehra, K.C. Potengi, F. Pinheiro; *Santa Casa de Limeira*, Limeira, São Paulo: P. Teixeira, J.F. Toledo, L. Gubolino; *Santa Casa de Marília*, Marília, São Paulo: A. Labrunie, P. Andrade, M. Tebet; *Santa Casa de Misericórdia de Juiz de Fora*, Juiz de Fora, Minas Gerais: A. Muniz, J. Loures, A. Abraão, M.S. Vankeulen, N.J. Pedroso; *Santa Casa de Porto Alegre*, Porto Alegre, Rio Grande do Sul: G. Nunes, A. Oliveira, C. Roehrig, I. Colnaghi; *Santa Casa de São Paulo*, São Paulo: F. Stella, M. Candeias, L. Scatamburlo, V. Kloth; *UNISUL Hospital Socimed*, Tubarão, Santa Catarina: S. Abreu, J. Lima.

Sources of Funding

The ACT is funded by the Brazilian Ministry of Health (Programa Hospitais de Excelência a Serviço do SUS). The sponsor had no role in analysis, study design, or decision to publish these results.

Disclosures

None.

References

1. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, Farid N, McManamon PJ. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. *N Engl J Med*. 1989;320:143–149.
2. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. *Am J Med*. 1997;103:368–375.
3. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, Lansky AJ, Moussa I, Stone GW, Moses JW, Leon MB, Mehran R. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. *Am J Cardiol*. 2005;95:13–19.
4. McCullough PA, Stacul F, Becker CR, Adam A, Lameire N, Tumlin JA, Davidson CJ. Contrast-Induced Nephropathy (CIN) Consensus Working Panel: executive summary. *Rev Cardiovasc Med*. 2006;7:177–197.
5. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. *Circulation*. 2002;105:2259–2264.
6. Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Machado Cesar LA, Seguro AC. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. *Nephrol Dial Transplant*. 2004;19:1803–1807.
7. Lopez BL, Snyder JW, Birenbaum DS, Ma XI. N-Acetylcysteine enhances endothelium-dependent vasorelaxation in the isolated rat mesenteric artery. *Ann Emerg Med*. 1998;32:405–410.
8. Heyman SN, Rosen S, Khamaisi M, Idee JM, Rosenberger C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. *Invest Radiol*. 2010;45:188–195.
9. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. *N Engl J Med*. 2000;343:180–184.
10. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. *Ann Intern Med*. 2008;148:284–294.
11. Nallamothu BK, Shojania KG, Saint S, Hofer TP, Humes HD, Moscucci M, Bates ER. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. *Am J Med*. 2004;117:938–947.

12. Bagshaw SM, McAlister FA, Manns BJ, Ghali WA. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. *Arch Intern Med.* 2006;166:161–166.
13. Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. *JAMA.* 2006;295:2765–2779.
14. Zagler A, Azadpour M, Mercado C, Hennekens CH. N-Acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. *Am Heart J.* 2006;151:140–145.
15. Gonzales DA, Norsworthy KJ, Kern SJ, Banks S, Sieving PC, Star RA, Natanson C, Danner RL. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. *BMC Med.* 2007;5:32.
16. Trivedi H, Daram S, Szabo A, Bartorelli AL, Marenzi G. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. *Am J Med.* 2009;122:874–815.
17. Benko A, Fraser-Hill M, Magner P, Capusten B, Barrett B, Myers A, Owen RJ. Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy. *Can Assoc Radiol J.* 2007;58:79–87.
18. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB III, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). *J Am Coll Cardiol.* 2006;47:1–121.
19. Wijns W, Kolh P, Danchin N, Di MC, Falk V, Folliquet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirtle C, Pomar JL, Reifart N, Ribichini FL, Schali J, Sergeant P, Serruys PW, Silber S, Sousa UM, Taggart D, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirtes PA, Tendera M, Vardas PE, Widimsky P, Kolh P, Alfieri O, Dunning J, Elia S, Kappetein P, Lockowandt U, Sarris G, Vouhe P, Kearney P, von Segesser L, Agewall S, Aladashvili A, Alexopoulos D, Antunes MJ, Atalar E, Brutel d'Or, Doganov A, Eha J, Fajadet J, Ferreira R, Garot J, Halcox J, Hasin Y, Hassens S, Kervinen K, Laufer G, Legrand V, Nashef SA, Neumann FJ, Niemela K, Nihoyannopoulos P, Noc M, Piek JJ, Pirk J, Rozenman Y, Sabate M, Starc R, Thielmann M, Wheatley DJ, Windecker S, Zembala M. Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J.* 2010;31:2501–2555.
20. Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA, Tumlin J. Strategies to reduce the risk of contrast-induced nephropathy. *Am J Cardiol.* 2006;98:59–77.
21. Caixeta A, Mehran R. Evidence-based management of patients undergoing PCI: contrast-induced acute kidney injury. *Catheter Cardiovasc Interv.* 2010;75:15–20.
22. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. *Circulation.* 2006;113:1799–1806.
23. Costa E, Reis H, de Assis GM, Cardoso GL, Barbosa MM, de Aguiar Filho FA, Gama CA, Silva MG, Aguiar BM, Ferreira MG, Feitosa GS, Victor Filho E, Rocha EB, Paiva MS, Czochra ER, Oliveira LA, de Oliveira IR, Pinheiro F, Dourado GO, Luna Filho AL, Pacheco A, Nunes PM, de Sá Filho AP, Martins HC, Lopes MA, Barros MA, Mattos C, Neves MA, Medeiros CR, Mattos C, Duarte L, Mattos C, Cramer H, Santos B Jr, Tura BR, Rodrigues CV, Terreiro LA, Alves MA, Soares JS, da Cunha CC, da Silva AC, Barcelos AM, Teixeira MA, Pinto JS, Saad JA, Mandil A, Falcheto E, Arêas CA, Dall'Orto FT, Freitas IF, Botelho RV, Seabra MD, Rosa CA, Pereira AD, Reis SS, Pereira VJ, Cunha SM, Ramalho GM, dos Santos RR, Muniz AJ, Loures JB, Amorim T, Muniz AJ, Loures JB, Abração AC, Padilha RM, Sousa JE, Sousa AG, Moreira AC, Sousa AG, Feres F, Centemero M, Costa R, Esteves V, Almeida BO, Janella BL, Almeida MC, Stella FP, Almeida JD, Kloth VR, Mangione JA, Mauro MF, Tallo F, Santos DJ, Castello H, Cantarelli MJ, Baradel S, Stella FP, das Candeias MO, Kloth VR, Maiello JR, Seixas EA, Teixeira PT, de Toledo JF, Gubolino LA, Prates GJ, Yokoyama H, de Almeida P, Pessoa CM, Machado NC, Garzon PG, Antonângelo AF, Galeazzi PB, Queirantes CS, Cavalini VH, Labrunie A, de Andrade PB, Tebet MA, Devito FS, Farias CE, Nicoleta EL Jr, Passos HM, Rubio P, Gubolino LA, Teixeira PT, de Toledo JF, Nunes GL, Roehrig C, de Oliveira AT, Wainstein MV, Ribeiro JP, Teixeira C, Atallah TN, Gomes C, Morelli H, Costantini CR, Tarbine SG, Santos MF, Ortiz CC, de Souza AB, Pecoits-Filho R, Koppe G, Hoffman PD, Faria Neto JR, Wang R, Cury C, Stadler N, Nercolini DC, Zanuzzi C, Bueno RR, Guerios EE, Tarastchuk JC, Peixoto ML, Labrunie A, de Andrade PB, Tebet MA, Thiago LE, Giuliano LC, Aranha FG, Misiak M, Thiago LE, Giuliano LC, Antunes MH, da Conceição RS, Abreu SM, Preve JC, Guimarães JS, de Araújo Filho D, Araújo EC, de Sousa LN, Fonseca AG, da Motta PA, Osterne EC, Da Motta VP, Zimmermann AC. Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropathy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy. *Trials.* 2009;10:38.
24. Bartholomew BA, Harjai KJ, Dukkupati S, Boura JA, Yerkey MW, Glazier S, Grines CL, O'Neill WW. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. *Am J Cardiol.* 2004;93:1515–1519.
25. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol.* 2004;44:1393–1399.
26. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care.* 2007;11:31.
27. Buyse M, George SL, Evans S, Geller NL, Ranstam J, Scherrer B, Lesaffre E, Murray G, Edler L, Hutton J, Colton T, Lachenbruch P, Verma BL. The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. *Stat Med.* 1999;18:3435–3451.
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials.* 1986;7:177–188.
29. Lefebvre C, Manheimer E, Glanville J; on behalf of Cochrane Information Retrieval Methods Group. Chapter 6: Searching for studies. In: Higgins JP, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions*. Chichester, UK: John Wiley & Sons Ltd.; 2008.
30. Kotlyar E, Keogh AM, Thavapalachandran S, Allada CS, Sharp J, Dias L, Muller D. Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures: a randomised controlled trial. *Heart Lung Circ.* 2005;14:245–251.
31. Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, Paolo EP, Golia B, Lepore S, Riviezzo G, Scarpato P, Focaccio A, Libreria M, Bonizzoni E, Ricciardelli B. Standard or double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. *Eur Heart J.* 2004; 25:206–211.
32. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. *BMJ.* 2001;323: 42–46.
33. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA.* 1995;273:408–412.
34. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De MM, Galli S, Fabbicocchi F, Montorsi P, Veglia F, Bartorelli AL. N-Acetylcysteine and contrast-induced nephropathy in primary angioplasty. *N Engl J Med.* 2006;354:2773–2782.
35. Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, Fuernau G, Erbs S, Linke A, Diederich KW, Nowak M, Desch S, Guterlet M, Schuler G. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate Percutaneous Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. *J Am Coll Cardiol.* 2010;55: 2201–2209.
36. Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al SA, Sutander A, Williams T, Fox RS, Levin A. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. *Am Heart J.* 2004;148:422–429.
37. Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Pietruck F, Janssen O, Philipp T, Kribben A. Early detection of acute renal failure by serum cystatin C. *Kidney Int.* 2004;66:1115–1122.
38. Hoffmann U, Fischeder M, Kruger B, Drobni W, Kramer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-

- induced nephropathy seems questionable. *J Am Soc Nephrol.* 2004;15:407–410.
39. D'Elia JA, Gleason RE, Alday M, Malarick C, Godley K, Warram J, Kaldany A, Weinrauch LA. Nephrotoxicity from angiographic contrast material: a prospective study. *Am J Med.* 1982;72:719–725.
 40. Jakobsen JA, Berg KJ, Kjaersgaard P, Kolmannskog F, Nordal KP, Nossen JO, Rootwelt K. Angiography with nonionic x-ray contrast media in severe chronic renal failure: renal function and contrast retention. *Nephron.* 1996;73:549–556.
 41. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. *AJR Am J Roentgenol.* 2004;183:1673–1689.
 42. Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and athero-embolism: a critical review. *Am J Kidney Dis.* 1994;24:713–727.
 43. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, Fan K, Lee CH, Lam WF. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. *JAMA.* 2003;289:553–558.

CLINICAL PERSPECTIVE

Contrast-induced acute kidney injury is associated with the need for dialysis, prolonged hospitalization, and mortality. Its incidence in patients with risk factors (kidney failure, diabetes mellitus, or advanced age) varies between 9% and 38%. Previous acetylcysteine trials had substantial risk of bias and were underpowered. We conducted a randomized trial of acetylcysteine versus placebo in 2308 patients at risk for contrast-induced acute kidney injury (age >70 years, renal failure, diabetes mellitus, heart failure, or hypotension) undergoing an intravascular angiographic procedure. Allocation was concealed; patients, health staff, and outcome assessors were blinded, and analysis followed the intention-to-treat principle. We administered 1200 mg of acetylcysteine or placebo every 12 hours, twice before and twice after the angiography. We found no effect of acetylcysteine on contrast-induced acute kidney injury, the primary end point (12.7% vs 12.7% in the acetylcysteine and placebo groups, respectively; relative risk, 1.00; 95% confidence interval, 0.81 to 1.25; $P=0.97$). There was also no effect on any of the secondary outcomes or for any subgroup. We conducted a meta-analysis to assess the results of the Acetylcysteine for Contrast-Induced Nephropathy Trial in the context of 45 trials on the same subject and found a huge variation in the effect on contrast-induced acute kidney injury, although those with adequate methodological criteria did not show any clinical benefit of acetylcysteine. In conclusion, our trial, the largest conducted to date, showed that acetylcysteine is ineffective to prevent contrast-induced acute kidney injury. Therefore, we do not recommend routine use of acetylcysteine for patients undergoing angiography.